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Anchit Bhagat, M.S.
Advisory Professor: Eugenie Kleinerman, M.D.

Doxorubicin (Dox) is one of the most effective chemotherapy agents that is used for the
treatment of childhood cancer. Unfortunately Dox treatment can cause damage to the heart.
Indeed, childhood cancer survivors are at a higher risk of developing a cardiovascular disease
at an earlier age. The mechanisms by which Dox causes acute and late cardiotoxicity are not
completely understood. One understudied area in Dox-induced cardiotoxicity is the
contribution of inflammation and innate immune cells, in particular neutrophils. Recognizing
that neutrophils have been implicated in a number of heart diseases, we evaluated the role of
neutrophils in Dox-induced cardiotoxicity. Here, using echocardiography, flow cytometry and
immunofluorescence staining, we demonstrated increased infiltration of neutrophils that
correlated with decreased heart function (as defined by a decrease in ejection fraction and
fractional shortening), disruption of vascular structures and increased collagen deposition in
the heart after Dox treatment. Depleting neutrophils protected the heart from Dox-induced
cardiotoxicity and changes in vascular structure both in the acute (24 hours after therapy) and
late stages (12 weeks after therapy). Furthermore, our data using neutrophil elastase (NE)
knock-out mice and the NE inhibitor AZD9668 suggest that neutrophils induce cardiac
damage by releasing NE and that inhibiting NE can prevent both acute and late Dox-induced
cardiotoxicity. Taken together, this data indicates the contribution of neutrophils and NE in
Doxorubicin-induced cardiotoxicity. This is the first demonstration of the importance of
neutrophils and NE in heart damage caused by Dox and suggests a potential new therapeutic
intervention.
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Chapter One: Introduction
This chapter is based upon “Bhagat A, Kleinerman ES. Anthracycline-Induced
Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol.
020;1257:181-192.”
Introduction to Anthracyclines
Anthracyclines are among the most effective chemotherapy agents used to treat
pediatric, adolescent, and adult patients with osteosarcoma

1.

In addition to

osteosarcoma and other sarcomas, anthracycline-containing regimens are used to
treat lymphoma, leukemia, and breast cancer, with 50–60% of childhood cancer
patients receiving an anthracycline-containing regimen during treatment 1. Some of
the commonly used anthracyclines are doxorubicin, mitoxantrone, epirubicin,
idarubicin, and daunorubicin. The structure of an anthracycline is composed of a
tetracyclic ring that is attached to a sugar. There are also quinone and hydroquinone
moieties present on adjacent rings, which permit the gain and loss of electrons.
Doxorubicin (Dox) is one of the more widely used chemotherapy agents in the
anthracycline family with respect to osteosarcoma. It, along with daunorubicin, was
the first to be used in clinical practice. Daunorubicin was identified first from the
bacterium Streptomyces peucetius. Dox, a derivative of daunorubicin, was identified
in the 1960s and found to be a more effective antitumor agent. With regard to
osteosarcoma, there is a correlation with dose intensity and patient survival. However,
there is also a correlation between the dose of Dox and late comorbidities which
results in compromised quality of life1. One of the most frequently seen late effects in

1

survivors of childhood cancer is cardiac disease. Sarcoma survivors are at a
significantly higher risk of being diagnosed with some form of cardiovascular event
compared to community controls. This is secondary to the high dose of Dox used to
treat these patients (450 mg/m2 vs 300 mg/m2 for breast cancer patients) 1. These
include vascular disease, cardiac dysfunction, myocardial infarction, arrhythmias,
dyslipidemia and essential hypertension. It is unclear whether the mechanism(s)
responsible for anthracycline-induced cardiotoxicity are the same as those that are
responsible for killing tumor cells.
In this chapter, we will review the identified mechanisms of action of
anthracyclines, and Dox in particular, since it is one of the major chemotherapy agents
used in the treatment of osteosarcoma. We will also summarize the cardiomyopathies
that have been documented in survivors treated with Dox and what has been
described in terms of monitoring patients for heart disease. This will include
investigations looking for early biomarkers to identify patients and survivors at risk.
Finally, we will summarize interventions aimed at decreasing anthracycline-induced
cardiotoxicity.
Mechanism of Antitumor Action
There are three proposed mechanisms by which Dox acts as an antitumor agent
2.

These include (i) intercalation into DNA strands, (ii) DNA damage by topoisomerase

suppression, and (iii) generation of free radical species and the subsequent cellular
damage including lipid peroxidation of cell membranes.

2

Intercalation into DNA strands
Dox has the capacity to inhibit DNA biosynthesis by DNA intercalation and
independent of inhibition of DNA polymerase activity. Dox intercalates into sites
containing adjacent GC base pairs. Additionally, the drug has an affinity for these sites
mainly due to hydrogen bond formation between Dox and guanine. This leads to the
formation of Dox-DNA adducts that can activate DNA damage responses and induce
cell death. This discovery has led to a few different approaches to increase the
antitumor efficacy of Dox. One such approach has been to combine with compounds
that release formaldehyde upon hydrolysis including pivaloyloxymethyl butyrate (AN9), butyroyloxymethyl-diethyl phosphate (AN-7), and hexamethylenetetramine
(HMTA) [3]. In some instances, this combination was effective in increasing the tumorkilling capacity of Dox. This is mediated by the stabilization of the covalent bond
between Dox and DNA by formaldehyde, resulting in an increase in the formation of
DNA adduct levels. However, contradictory data makes it difficult to establish the DNA
adduct formation as the major mechanism of Dox-mediated tumor cell killing 3.
DNA damage by topoisomerase suppression
DNA topoisomerases are enzymes that play essential roles in the unwinding and
rewinding of the DNA helix strands during replication, transcription, and
recombination. The need for topoisomerase arises due to the double-helical nature of
the DNA strand. In order to access information stored in DNA, the two strands of the
helix must be separated temporarily. There are two main types of topoisomerase
depending on whether there is a single- or double-stranded break in the DNA helix.
Type I isomerase causes a single-stranded break, while Type II cuts both strands of
3

the DNA helix 4. For the purposes of this discussion, Type II topoisomerase, which
consists of Top2α and Top2β, will be discussed. In malignant cells that are
proliferating rapidly, Top2α is more highly expressed. Top2α works in an adenosinedependent fashion by recognizing a DNA substrate (G segment) and causing a
double-stranded break which opens one of the DNA duplex. This helps facilitate the
capture and entry of a second DNA piece termed the T segment through the opening
in the G segment. This helps unwind the DNA strand and is followed by re-ligation of
the double-stranded break in the G segment. Failure in this process results in DNA
lesions that lead to mitotic and apoptotic cell death 5.
Dox targets Top2α which is highly expressed in osteosarcoma cells 6. Dox
intercalates into DNA and prevents Top2 from binding with DNA. This leads to the
suppression of the Top2-DNA cleavage complex formation with subsequent
transcriptional arrest, which then leads to DNA damage and ultimately cell death.
Generation of free radical species
Anthracylines including Dox induce the generation of free radicals 7. Reactive
oxygen species and reactive nitrogen species are collectively termed free radicals,
molecules with one or more unpaired electrons in their outer shells. Free radicals
include hydroxyl (OH•), superoxide (O2•–), nitric oxide (NO•), nitrogen dioxide (NO2•),
peroxyl (ROO•), and lipid peroxyl (LOO•) 8. Under homeostatic conditions, these free
radicals act as an integral part of the host defense system and aid in maturation of
cellular structures. However, when produced in excess, these free radicals give rise
to oxidative stress due to an imbalance between formation and the elimination of the
free radical species. This can ultimately lead to damage to cell membranes by a
4

process called lipid peroxidation 9,10. Dox has a quinone structure which allows for the
drug to act as an electron acceptor which is mediated by other oxoreductive enzymes
such as cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase.
This addition of the free electron facilitates the conversion of the quinone to a semiquinone free radical. Once these free radicals are generated, they then induce freeradical injury to DNA. Unlike the DNA damage associated with inhibition of
topoisomerase II, this damage is not associated with proteins 11. This DNA damage
can be prevented by superoxide dismutase, catalase, and glutathione peroxidase. For
this reason, it has been observed that free radicals generated by Dox toxicity result in
the alterations of glutathione levels which in turn have an impact on cell sensitivity to
Dox 11. However, studies conducted have reported mixed findings as to whether free
radical generation is one of the main mechanisms by which Dox can cause damage
to tumor cells.
Cardiotoxicity
Cardiovascular disease and heart failure are the most common late effects which
compromise quality of life and the long-term survival for sarcoma survivors

11.

Dox-

induced cardiotoxicity can be debilitating and an often-deadly consequence of
successful tumor treatment. The acute damage of the juvenile heart caused by Dox
makes the adult heart more vulnerable to stresses over time, putting the heart at risk
for ischemic damage, and predisposing to late-onset cardiomyopathies at a much
earlier age. Thus, a minor ischemic event that would cause minimal or no damage in
a healthy individual would result in more significant damage in a heart previously
damaged by Dox. Cardiotoxicity is defined as the inability of the heart to pump blood
5

through the body effectively. In 2014, there were 14.5 million cancer survivors 1. This
number is expected to increase to 18 million by 2020, indicating that this late effect
will be seen in increasing numbers. One risk factor associated with the Dox-induced
cardiotoxicity is age of the patients, with children under 4 years and adults over 65
years of age being at a higher risk of developing cardiotoxicity. Furthermore, Lipshultz
SE et al. have also reported that females had more severe cardiotoxicity with more
compromised contractility 1. It is estimated that 60% of pediatric patients receive an
anthracycline-containing treatment regimen and 10% of these are expected to develop
symptomatic cardiomyopathy up to 15 years after completing therapy 1. Another study
reported the incidence of subclinical and overt cardiotoxicity to be 17.9% and 6.3%,
respectively, in cancer patients treated with anthracyclines after 9 years of follow-up
12.

Thus, cardiotoxicity can develop after a significant amount of time has passed after

completion of treatment indicating that long-term cardiac monitoring of survivors is
essential. One factor that contributes to the development of the cardiotoxicity is the
dose of Dox used in the cancer treatment. In patients who received more than 500
mg/m2 of anthracyclines, a 63% prevalence of left ventricular dysfunction after 10
years of follow-up was reported, in contrast to an 18% prevalence in those who
received less than 500 mg/m2 13. Another study reported that in patients who received
a cumulative dose of 400 mg/m2, there was a 5% risk of developing heart failure which
increased to 25% at 700 mg/m2 2. This is indicative of the fact that the risk of
cardiotoxicity correlates with increased drug dose. However, another separate study
looking at the histopathological changes in endomyocardial biopsy specimens from
patients concluded that there is no particularly safe dose of Dox 2. Unfortunately, the

6

exact mechanism of Dox-induced cardiotoxicity is unknown but there are several
proposed molecular mechanisms.
Definition and detection of cardiotoxicity
Cardiotoxicity is defined by a number of different parameters. These include (1)
reduction of left ventricular ejection fraction (LVEF), either global or specific in the
interventricular septum; (2) symptoms or signs associated with heart failure (HF); (3)
reduction in LVEF from baseline to lesser 55% in the presence of signs or symptoms
of HF; or (4) a reduction in LVEF greater than or equal to 10% or an LVEF lesser than
55% without signs or symptoms of HF

14.

Left ventricular ejection fraction is defined

as the central measure of left ventricular systolic function and is the fraction of volume
ejected during the contraction phase(systole) of blood circulation in relation to the
volume of blood in the ventricle at the end of the dilution phase (diastole). Normal
LVEF for males is 52–72%, while for females, it is 54–74%. Less than 52% LVEF is
considered abnormal and suggests compromised heart function 15.
There

are

several

different

methods

to

detect

anthracycline-induced

cardiotoxicity. One of the most successful methods is an endomyocardial biopsy.
However, this technique has several limitations: first, it is invasive and second, with
regard to the quality of the sample and whether the sample obtained by the biopsy
contains damaged myocardium. It is for these reasons that noninvasive methods are
preferred. One of the most widely used methods in this regard is echocardiography.
Using this technique, the left ventricular ejection fraction, which is an indicator of
cardiac systolic function, can be quantified. A study conducted on 1664 patients who
were treated with anthracyclines as part of their breast cancer treatment showed that
7

the absolute value of pretreatment LVEF was indicative of a later occurrence of heart
failure. Despite its effectiveness in adult patients, there have seen some discrepancies
regarding its predictive value in children treated with anthracyclines

16.

Some of the disadvantages of standard 2D echocardiography are the following:
(i) the quality of images obtained determines the accuracy of the LVEF measurement,
(ii) ventricular foreshortening can contribute toward lack of accuracy in measured
LVEF, and (iii) use of mathematical models and geometrical assumptions to calculate
LV volumes

16.

As a result, there have been further enhancements made to the

echocardiography technique including use of contrast agents to help highlight the
endocardial border and improve tracing of the end-systolic and end-diastolic volumes.
Additionally, 3D echocardiography has helped with reducing analysis time and
interobserver variability 16.

Monitoring Cardiotoxicity and Heart Function
Biomarkers to identify acute cardiotoxicity and predict late cardiac effects: Early
detection of at-risk patients for cardiotoxicity combined with early intervention could
help decrease the occurrence of heart failure in survivors. To address this need, many
studies have been conducted to try to determine serum and plasma biomarkers that
are relevant to cardiotoxicity and predicting which patients are at risk for developing
cardiotoxicity and heart failure 17. Unfortunately, such suitable biomarkers have yet to
be identified that both document acute heart damage and correlate with the
development of heart failure. However, what is established is that elevated levels of

8

troponin and natriuretic peptides are two biomarkers that are associated with acute
coronary syndrome and heart failure, respectively

17.

We will now discuss these with

regard to identifying anthracycline-induced cardiotoxicity, monitoring for heart failure,
and/or predicting patients at risk for late cardiotoxicity.
Cardiac troponins
Troponins are proteins that are found in skeletal, cardiac, and smooth muscles
17,18.

Troponin T (TnT) and troponin I (TnI) are both exclusively found within cardiac

myocytes. Upon damage to cardiomyocytes, troponins T and I are released into
circulation. Elevated troponin levels indicate cardiac damage and LV dysfunction 17,18.
Investigations looking at cardiac troponins with relevance to cardiotoxicity have
concentrated on early onset heart damage. What has been observed is that early
troponin elevation preceded changes in LVEF. In a study of 703 patients with breast
cancer and lymphoma, it was seen that TnI elevation measured within 72 h as well as
1 month after chemotherapy administration had significantly greater risk of developing
cardiotoxicity over a mean follow-up of 20 months 17. Another study looked at changes
in TnI and LVEF after cycles of high-dose anthracycline-containing chemotherapy in
204 patients. It was found that patients who had elevated TnI had significant reduction
in their LVEF 7 months after completion of treatment

18.

From this standpoint, it

suggests that looking at troponin levels at an acute stage of cardiotoxicity may be
useful. However, other studies conducted found no correlation between troponin level
and the development of late heart failure due to the use of anthracycline. One such
study looked at 150 childhood and 53 adult cancer survivors with hematologic
malignancies and breast cancer, respectively
9

19.

It was found that there was no

detectable elevation of TnT or TnI after a 2-year and 1-year follow-up confirming that
there is a lack of correlation between troponin and LV dysfunction, particularly in
childhood cancer survivors.
Natriuretic peptides
These are peptide hormones that include atrial natriuretic peptides (ANP) and
brain natriuretic peptides (BNP). These peptides promote natriuresis and help with the
protection of the heart from mechanical stress and volume overload. Published
literature illustrated an early association between anthracycline-induced cardiotoxicity
and brain natriuretic peptides. In one study, 71 breast cancer patients received 6
cycles of liposome-encapsulated Dox (40–50 mg/m2), docetaxel (50 mg/m2), and
epirubicin (90 mg/m2) in combination with fluorouracil and cyclophosphamide. Upon
completion of the treatment cycle, it was observed that BNP levels were elevated and
that the elevation 24 h after treatment was associated with reduction in LVEF.
However, other studies failed to show a link between elevated natriuretic peptides and
late-onset cardiotoxicity. The reason for this discrepancy could be that elderly
individuals and females have higher than normal natriuretic peptide levels.
Additionally, compromised renal function can increase natriuretic peptide levels.
Finally, cancer itself may increase BNP levels through inflammation. Indeed, patients
with metastatic disease were found to have higher levels of BNP than those without
metastasis19.

10

Myeloperoxidase
Another potential biomarker is myeloperoxidase, a pro-inflammatory enzyme that
is expressed by neutrophils. Myeloperoxidase is an indicator of oxidative stress and
is induced following damage to the myocardium by reactive oxygen species
generation and is part of the inflammatory response. In one study conducted on 78
breast cancer patients treated with Dox as part of their chemotherapy regimen,
patients with increased MPO levels along with elevations in TnI over a 15-month time
period had a 46.5% increased risk for developing cardiotoxicity

19.

However, further

studies are needed to confirm this finding.
MicroRNAs
Several studies have also explored microRNAs as viable biomarkers for
anthracycline-induced cardiotoxicity. These are small non-coding RNA molecules that
aid in regulation of gene expression. Some of the common cardiac miRNAs under
investigation include miR-1, miR-133, miR-208, and miR-499. In myocardial infarction
models in both humans and animals, miR-208 and miR-499 are found to be elevated.
These two microRNAs are also specifically found in cardiac myocytes. In a study of
33 children with anthracycline exposure, it was observed that there was elevation in
plasma levels of miR-29b and miR-499, and this correlated with rise in troponin levels
and increase in dose of anthracyclines. In a separate study of breast cancer patients
who were treated with Dox, there was an increase in miR-1 that was associated with
decline in LVEF. The monitoring of miRNAs therefore may provide a potential new
biomarker for assessing and monitoring early- and late-onset cardiotoxicity, as

11

microRNAs are present in all body fluids, have a long half-life, and are relatively stable
under extreme temperatures and pH 17.
Mechanisms of Anthracycline-Induced Cardiotoxicity
The exact mechanism(s) by which Dox induces cardiotoxicity is poorly
understood. This section summarizes several of the proposed mechanisms.
Oxidative stress
The most frequently proposed mechanism for Dox-induced cardiotoxicity is the
generation of reactive oxygen species followed by lipid peroxidation

20

. Some of the

common reactive oxygen species generated include superoxide(O2−), hydroxyl
radicals (OH), hydrogen peroxide (H2O2), and singlet oxygen (O2). A low level of
oxidant species is necessary for normal transduction process; however, if these levels
exceed the threshold level, this can be damaging to cells. The myocardium is
especially vulnerable as there are lower levels of the antioxidant enzymes peroxidase,
catalase, and superoxide dismutase present in the heart. Peroxidase helps catalyze
oxidation of substrates and uses hydrogen peroxide as the electron acceptor. This
helps with elimination of the toxicity of hydrogen peroxide and oxidizes phenols,
amines, and hydrocarbon oxidation products. Catalase helps with the decomposition
of H2O2 and removal of H2O2, thereby protecting cells from H2O2 poisoning. Due to
a lack of these enzymes, there is an accumulation of H2O2 which leads to damage 20.
One of the major subcellular targets of Dox is the mitochondria 21. The number of
mitochondria in cardiomyocytes is increased by 35–40%. In the mitochondria, ROSproducing enzymes transform the quinone moiety present in Dox to a semi-quinone
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through a one electron reduction. Semiquinones can then be converted to a
superoxide anion by reaction with oxygen. These superoxide anions can then be
transferred to ROS or reactive nitrogen species via the redox cycle. However, high
levels of these superoxide anions can produce highly reactive and toxic hydroxyl
radicals during a reaction catalyzed by iron called the Fenton reaction

21.

As mentioned earlier, a lack of antioxidant enzymes in the myocardium means
the heart is more vulnerable to oxidative stress. Furthermore, with a higher number of
mitochondria in the cardiomyocytes, this leads to a higher production of ROS once
Dox binds to the mitochondria and initiates the production of superoxide anions which
in turn can produce toxic hydroxyl radicals and in turn higher oxidative stress.
Cardiolipin, a phospholipid, is a component within inner mitochondrial membrane
which Dox has a high affinity for

22.

As a result, an irreversible complex is formed

between Dox and cardiolipin that accumulates on the inner mitochondrial membrane.
This complex can then lead to mitochondrial dysfunction through oxidation of enzymes
that are catalyzed by cardiolipin. This creates a disturbance of the electron transport
chain in mitochondria as proteins, including cytochrome C oxidase, cytochrome C
reductase, and NADH dehydrogenase, are oxidized which subsequently leads to
energy reduction and apoptosis of cells as 90% of the ATP utilized by cardiomyocytes
is produced by the mitochondria

21.

One other proposed mechanism of oxidative stress is the “ROS and Iron”
hypothesis23. As mentioned earlier, iron catalyzes the Fenton reaction that is needed
to convert the superoxide anions to hydroxyl radicals. Dox can form a complex with
iron which can potentially lead to excessive ROS production causing apoptosis of
13

cardiac cells. This accumulation of iron in mitochondria is facilitated by members of
the ABC protein family particularly ABC protein B8(ABC8). ABC8 has a role in
mitochondrial iron homeostasis and helps with facilitating mitochondrial iron export.
One study conducted showed that Dox downregulated the ABC8 protein and mRNA
levels which in turn affected the export of iron from the mitochondria leading to
excessive accumulation of iron in the mitochondria which is toxic to the cells. By
contrast, levels of another protein, mitoferrin 2, were found unchanged. Mitoferrin 2 is
involved in mitochondrial import of iron. The alteration of iron export while maintaining
levels of iron import leads to excessive iron and to a disturbed state of iron
homeostasis in mitochondria

23.

Another mechanism through which iron overload is

caused is through the interaction of Dox with iron-transporting and iron-binding
proteins including IRP (iron regulatory protein). As mentioned earlier, Dox can form a
complex with iron, and this complex reduces the amount of free iron 24. This free iron
is then unable to bind to IRP. This leads to inactive IRPs which then bind with ironresponsive elements (IREs) which in turn leads to a disruption of proteins related to
iron metabolism. This disruption leads to a decrease in synthesis of ferritin and
upregulation of transferrin receptor (TfR) that leads to increase in iron levels which
disturbs the iron homeostasis 24.
Nicotinamide adenosine dinucleotide phosphate is another enzyme that helps
with generation of free radicals by the redox cycle

20.

These are a group of plasma

membrane-associated enzymes that serve as a source of ROS. Similar to what has
been discussed earlier, nicotinamide adenine dinucleotide phosphate (NADPH)
oxidases (NOX) helps with conversion of quinone moiety to a semi-quinone radical

14

that can react with oxygen to generate hydrogen peroxide. NOXs can be activated by
many stimuli including TNF-a and are pivotal in cardiac remodeling

20.

Furthermore,

Nox 2 was found to be the main mediator of NOX-derived ROS.
Nitric oxide is also a major source of Dox-induced oxidative stress. In normal
homeostatic conditions, nitric oxide is a vasodilator that mediates heart contractions.
An elevated level of NO is observed in Dox-induced cardiotoxicity due to isoforms of
NOS, namely, endothelial NOS, inducible NOS, and neuronal NOS

25.

Dox captures

electrons from NADPH by directly binding the reductase domain of eNOS. This helps
with superoxide formation. The role of eNOS was confirmed in a study conducted on
eNOS knockout mice that displayed low levels of ROS and preserved myocardial
function after exposure to Dox. Basal production of NO is needed to modulate
cardiomyocyte contractility and blood flow distribution

25.

However, higher levels of

NO production via INOS are associated with dilated cardiomyopathy and congestive
heart failure7.
There are multiple sources of oxidative stress in the myocardium. Reactive
oxygen species that generates the oxidative stress overwhelms cardiomyocyte
enzymatic defenses and alters gene expression through interaction with regulatory
proteins. ROS also can affect function of G proteins via lipid peroxidation. Despite this
overwhelming connection between oxidative stress and Dox-induced cardiotoxicity,
the experimental evidence that treating this oxidative stress will reduce Dox-induced
cardiotoxicity has not been conclusive.
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Cardiomyocyte apoptosis
Oxidative stress can activate apoptotic signaling that leads to cardiomyocyte
apoptosis. In this scenario, both extrinsic and intrinsic pathways are involved.
However, apoptosis can be induced via an oxidative stress-independent manner. The
B-cell lymphoma 2 (Bcl 2)-Bcl-2-like protein 4 (bax) ratio is important in apoptosis and
involves heat shock proteins

25.

These proteins act as molecular chaperones and

stabilize other proteins involved in anti-apoptotic signaling by preventing
dephosphorylation, ubiquitination, and degradation. The heat shock proteins that are
important in having a role in the cardiac microenvironment include heat shock protein
27 (Hsp27), heat shock protein 10 (Hsp10), and heat shock protein 60 (Hsp60). In a
study conducted by Liu et al., they found that overexpression of Hsp27 prevented Doxinduced apoptosis and myocardial dysfunction 26. In another study, overexpression of
Hsp10 and Hsp60 was found to shift toward an anti-apoptotic pathway due to
increased posttranslational modification of Bcl-2 protein26. Hsp20 aids in maintenance
of Akt phosphorylation which is one of the main cell survival pathways. Heat shock
proteins also act as ligands for Toll-like receptors (TLR) after being secreted into the
bloodstream

26.

In addition to its effect on modification of Bcl-2, Hsp60 interacts with

TLR-2, while Hsp70 interacts with TLR-4

20.

The exact role of Toll-like receptors in

Dox-induced cardiotoxicity is not well-defined as yet; however, studies conducted
indicate that apoptosis is initiated by TLR-2- and TLR-4-mediated signaling through
pro-inflammatory NFκB post Dox treatment 26.
Dox also influences caspase activity. In particular, caspase-3 activation is
associated with Dox administration in vivo. In one study, suppression of caspase
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activity in cardiomyocytes was achieved through the administration of NO donor Snitrosyl-N-acetyl-penicillamine. In another study, blocking of volume-sensitive chloride
channels prevented Dox-induced caspase-3-dependent apoptosis 27. It has also been
observed that Dox elevated the expression of death receptors such as tumor necrosis
factor receptor 1 (TNFR1), fas cell surface (Fas) death receptor, DR4, and DR5 in
cardiomyocyte. This elevated expression leads to activation of caspase cascade 20.
Calcium dysregulation
Control of calcium levels is important in cardiomyocytes as calcium aids in
regulating contractile activity26. Intracellular calcium levels are increased in Doxinduced cardiotoxicity. The ROS and H2O2 that are generated can alter normal
calcium homeostasis in several different muscle types including the heart by disrupting
normal sarcoplasmic reticulum. By inhibiting the Ca2+ ATPase pump and reducing
the expression levels of SERCA2a MRNA, the free radicals can impair Ca2+
metabolism

20.

Dox can also induce the release of calcium from sarcoplasmic

reticulum by promoting the opening of the calcium channels. Dox has also been shown
to inhibit the sodium-calcium exchanger channel in the sarcolemma26.
Caspase-12 activates apoptotic pathways, and its activation is dependent on
calpain dysregulation which sends out signals of distress from sarcoplasmic reticulum
26.

Calpains are proteases that are activated by calcium. Much of the intracellular

calcium in cardiomyocytes is present in the sarcoplasmic reticulum. Oxidative stress
can cause calcium leakage, calpain activation, and caspase-12 cleavage. Calpains
have been found to degrade titin which is a large protein and a key component of
cardiac sarcomere which helps in maintaining cardiac contractility
17

26.

Hence,

prevention of calpain activity helps maintain contractility after Dox exposure

20.

Dox

has also been found to enhance the sensitivity of mitochondria to intracellular calcium
26.

In a study conducted in rats, it was found that mitochondria of cells in Dox-treated

heart had a decreased ability to retain calcium

26.

Another possible mechanism by which Dox can affect calcium intracellular
concentrations is through regulation of its metabolism. Dox can generate a toxic
metabolite, namely, DOXol, which inhibits the sodium-calcium exchanger channel

28.

DOXol can also disrupt the sodium gradient that is needed for calcium to flow into
sarcolemma of a cardiomyocyte. This leads to an imbalance in energetics of the
myocardium and diminished systolic function. DOXol accumulation can thus
contribute significantly to dysregulation of calcium homeostasis leading to myocardial
damage 29.
Immune system
Studies have shown that elevated levels of IL-1β, IL-6, and TNFα, all proinflammatory markers, are elevated following Dox therapy

30.

As discussed above,

Dox can activate the NFκB pathway which enhances inflammatory mediators as
mentioned above along with vascular endothelial growth factor (VEGF) and matrix
metalloproteinases (MMP2)

30.

Phosphorylation of IκB is mediated by Iκκ and is an

important step in NF-Κb activation. In one study, it was observed that there was a
significant increase in Iκκα expression in heart following Dox treatment and that this
increase was observed after only 24 h of a single dose

30.

This indicates that Dox

treatment can induce a quick activation of transcription factors.
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Toll-like receptors (TLRs) have also been shown to be involved in Dox-induced
cardiotoxicity 26. Toll-like receptors are part of a family of pattern recognition receptors
that act to detect danger signals including pathogens, oxidative stress among many.
The role of TLRs in cardiovascular diseases will be described in greater detail in
chapter 2.
Prevention of Dox-Induced Cardiotoxicity
Dexrazoxane
Dexrazoxane is the only FDA-approved cardioprotective agent for anthracyclineinduced cardiotoxicity31. Dexrazoxane is an adjunctive agent that can act as a free
radical scavenger. It is converted into a ring-opening chelating agent and can replace
iron in the Dox Fe3+ complex and combine with iron. In this manner, dexrazoxane
interferes with iron ion-mediated free radical production, weakening the cardiotoxic
immune effector cells and blocking the inactivation of respiratory enzymes by iron
complexes. Additionally, dexrazoxane can chelate iron and prevent ROS through nonenzymatic mechanism of Dox.
Many studies have been done to determine the efficacy of dexrazoxane in
preventing Dox-induced cardiotoxicity. In a group of 200 children with acute
lymphoblastic leukemia (ALL) who had received a cumulative Dox dose of 300 mg/m2,
blinded troponin T measurements were taken at different time points before, during,
and after Dox infusion

11.

These children were randomized to receive Dox plus

dexrazoxane or Dox alone. At the end of treatment, it was found that 20% of children
who had been given both Dox and dexrazoxane had elevated TnT levels as opposed
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to 47% who only received Dox

11.

Furthermore, in a 5-year follow-up, left ventricular

fractional shortening was found to be lower in children who were treated with Dox
alone as opposed to those who were treated with both Dox and dexrazoxane. In
another study conducted by Cheng et al. in BALB/c mice with and without tumors, it
was found that mice treated with Dox plus dexrazoxane showed normal heart tissues
morphologically with no characteristic inflammation or tissue injury 11.
However, a major concern with regard to use of dexrazoxane as a
cardioprotectant is the potential risk of secondary malignancy

11.

It is for this reason

that currently the Food and Drugs Administration (FDA) has approved the use of
dexrazoxane only in women with metastatic breast cancer who received cumulative
doses of 300 mg/m2

32.

There have been studies conducted however to disprove

these findings. In one large study, in pediatric patients with acute lymphoblastic
leukemia, it was observed that for children who received dexrazoxane, the occurrence
of a secondary malignancy was a rare event. In the study conducted for 553 pediatric
patients with ALL, only 1 developed acute myeloid leukemia in a median follow-up
period of 5 years. In another group, there was no significant difference reported in
incidence of secondary malignancy in pediatric ALL patients (n = 173) who received
dexrazoxane as compared to placebo (n = 150) 6. This seems to suggest that the risk
for developing secondary malignancy using dexrazoxane is low, but the FDA
recommendation is that this cardioprotectant not be used for pediatric patients until
further studies are done.
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ACE inhibitors and beta-blockers
Angiotensin-converting enzymes (ACE) are a mainstay in the treatment of heart
failure

20.

Angiotensin is a peptide hormone that is involved in regulating blood

pressure. Angiotensin-converting enzyme is part of the renin-angiotensin system that
controls blood pressure by converting the angiotensin I to an active vasoconstrictor
angiotensin II. Therefore, ACE can cause an increase in blood pressure by causing
vessels to constrict. Hence ACE inhibitors, including enalapril, zofenopril, and
lisinopril, have been used to treat heart failure

20.

These drugs can act as an

antioxidant as it was observed that administration of enalapril helped attenuate Doxinduced cardiac dysfunction by preserving mitochondrial respiratory efficiency and
reducing free radical generation. However, for long-term use, the effectiveness of
these drugs in childhood cancer survivors diminishes after 6–10 years 20. Furthermore,
ACE inhibitors could also have adverse side effects, and hence use of these agents
for cardioprotection needs to be monitored.
Beta-blockers, including carvedilol, have been shown to preserve left ventricular
function after Dox treatment in patients as compared to placebo 26. Beta-blockers work
by blocking adrenaline and reducing blood pressure. Additionally, early addition of βblockers and angiotensin-converting enzymes has been shown to improve myocardial
contractility in Dox-induced cardiotoxicity

26.

However, Georgakopoulos et al.

demonstrated that metoprolol, a β-blocker without antioxidative properties, was not
able to provide cardioprotection in lymphoma patients treated with Dox 11.
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Other cardioprotectants
Antioxidants including resveratrol have been used in acute Dox treatment to
significantly decrease ROS generation which in turn improved glutathione, superoxide
dismutase, and catalase activity

26.

This helps with improving cardiac function.

Erythropoietin (EPO) is a cytokine that stimulated the production of red blood cells in
the bone marrow. EPO can act as a cardioprotective agent against Dox-induced
apoptosis26. Another drug sildenafil, a phosphodiesterase 5 inhibitor, has been used
to attenuate cardiomyocyte apoptosis and preserve the mitochondrial membrane
potential to maintain myofibril integrity and prevent left ventricular dysfunction in a
mouse model of Dox-induced cardiotoxicity 26. Pretreatment with sildenafil maintained
mitochondrial integrity by augmenting cellular mechanisms mediated by NO/cyclic
GMP.
Another cardioprotective agent is monoHER which is the main constituent of
flavonoids Venoruton

26.

In an in vivo and ex vivo mouse model, pretreatment with

monoHER protected against Dox-induced cardiotoxicity and additionally did not
interfere with the antitumor effect of Dox. However, more studies are needed to
demonstrate the efficacy of this agent. There is also new evidence that cardiacα1adrenergic receptors can protect from Dox-induced cardiotoxicity by protecting
cardiomyocytes

26.

Stimulation of these receptor agonists, including phenylephrine

and dabuzalgron, reduces apoptosis and interstitial fibrosis and in turn decreases
myocardial dysfunction caused by Dox

26.

This effect was associated with anti-

apoptotic proteins of the Bcl2 family and preserving mitochondrial function.
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Exercise intervention
Aerobic exercise has been shown to have cardioprotective effects and is
recommended by the American Heart Association to promote cardiac health and in
particular for cancer survivors of all ages 33. Recently, in a study by Wang et al., it was
observed that aerobic exercise was an effective intervention in mitigating acute
cardiac side effects in juvenile mice treated with Dox 33. The Dox-induced reduction in
ejection fraction and fractional shortening were found to be prevented by exercise in
mice that had been treated with Dox. Additionally, it was found that Dox caused a
reduction in body weight and the heart weight: tibia length ratio in tumor-bearing mice
that were treated with Dox alone. However, the exercise intervention administered
during therapy helped mitigate this weight loss and prevented the reduction in heart
weight: tibia length ratio. The exact molecular mechanism(s) by which exercise had
this cardioprotective effect in mice treated with Dox is yet to be determined.
Additionally, the cardioprotective benefits of exercise were also seen when the
exercise was initiated after Dox therapy 33,34.
Targeting the Immune system
Recent studies have begun to focus on the contribution of inflammation and an
inflammatory response to cardiotoxicity, particularly the role of innate immune cells
and the cytokines these cells produced. A more in-depth understanding of these
parameters has the potential to identify mechanisms and interventions such as
blocking cytokine/chemokine production, to reduce the impact of Dox-induced
cardiotoxicity.
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Chapter Two: The Innate Immune System in Cardiovascular Diseases
Inflammation in the heart
Inflammation that occurs due to trauma or chemically induced injury and in the
absence of pathogens is termed ‘sterile inflammation’. In the case of cardiac
injury/damage, sterile inflammation forms the foundation of the first phase of cardiac
remodeling

and involves the production of chemokines and cytokines and the

recruitment of innate immune cells such as neutrophils and macrophages

35.

During

the inflammation phase, the pathogenic source of infection danger signals is detected
by certain pattern recognition receptors (PRRs) include Toll-like receptors (TLRs),
nucleotide-binding and oligomerization domain (NOD) like receptors and C-type lectin
receptors. In a similar manner, when there is tissue damage, endogenous molecules
related to the injury are released as damage associated molecular patterns (DAMPs).
These DAMPs can also be detected by PRRs. Once these danger signals are
detected, an inflammatory cascade is activated. This cascade includes the release of
cytokines/chemokines, the activation of inflammatory pathways, and the subsequent
recruitment of immune cells from circulation and bone marrow. These processes are
meant to clear damaged tissue and other necrotic cells to move to the next phase of
repair.i.e. deposition of new extracellular matrix (ECM). At first this is a necessary
process to maintain homeostasis and modulate repair. However, unchecked
activation leads to chronic inflammation and is detrimental.
Cardiac remodeling post ischemic injury occurs in three phases: inflammation,
granulation and maturation. The inflammatory phase is characterized by an increase
in pro-inflammatory cytokines and chemokines, such as interleukin 1 (IL-1), IL-6, IL-8,
24

TNFα, granulocyte colony-stimulating factor (G-CSF), GM-CSF, CXCL-1. This leads
to the recruitment of neutrophils and subsequently macrophages, two essential
components of the myeloid system

36.

The granulation phase involves ECM turnover

and differentiation of cardiac fibroblasts and the final maturation phase includes
deposition of new ECM including collagen. Excessive deposition of collagen however
can lead to fibrosis, and subsequently heart failure. Cardiac fibrosis is a characteristic
of several conditions, such as cardiomyopathy, myocardial infarction (MI), pressure
overload, and the aging process37.
Pattern Recognition Receptors
Toll-like Receptors
In patients with MI, endogenous DAMPs are released from damaged cells and
detected by TLRs and other PRRs, which initiate a signaling cascade. These DAMPs
include: heat shock proteins, S100 proteins, uric acid, high mobility group box protein
1 (HMGB1), and endogenous nucleic acids. Additionally, components of the ECM,
such as hyaluronan, heparan sulfate and proteoglycans can also act as DAMPs. 35
TLRs comprise 3 structural domains: an extracellular C-terminal leucine-rich repeat
domain, a central transmembrane domain, and a cytoplasmic domain. TLR signaling
occurs via two main pathways: the MyD88-dependent and TRIF-dependent pathways.
In the MyD88-dependent pathway, there is first a recruitment of a Toll/IL-1
receptor domain containing adaptor protein that initiates TLR4/2 related signaling.
This leads to activation of the downstream IL-1 receptor-associated kinase 4(IRAK4),
induction of IRAK1 phosphorylation, and recruitment of TNF-receptor-associated
factor-6 (TRAF6). Phosphorylated TRAF6 forms a complex with transforming growth
25

factor β-activated kinase (TAK- 1), TAK1-binding protein-1(TAB1), and TAB2. This
complex then interacts with ubiquitin ligases to activate the TAK1. Next, activated
TAK1 phosphorylates the IKK complex and p38 kinases. The IKK complex will then
phosphorylate I-κB. I-κB’s subsequent ubiquitylation and degradation leads to NF-κβ
translocation to the nucleus, which in turn leads to pro-inflammatory cytokine
production.38
TLRs also signal through the TRIF-dependent pathway which involves signaling
via TRIF- related adaptor molecule (TRAM) and TRIF. This signaling activates TANK
Binding Kinase-1 (TBK1) and the eventual activation of interferon- regulatory factor-3
(IRF3). TRIF-dependent signaling can also occur through NF-κβ via TRAF6
recruitment as described above.39
Inflammasome
Activation of the NF-κβ pathway can lead to the expression of inflammasome
components. In particular, the NLRP3 inflammasome has been shown to be induced
in cardiovascular diseases. This cytosolic protein consists of three domains: a Cterminal leucine-rich repeat domain, a NOD also called a NACHT domain, and an Nterminal pyrin domain. NLRP3 binds to an adaptor protein, apoptosis-associated
speck-like protein containing a caspase recruitment domain (ASC). ASC binds to procaspase 1 and activates it. The active caspase 1 cleaves its substrates including proIL-1β and pro-IL-18. This leads to extracellular release of mature IL-1β and IL-18.
These two cytokines have been implicated in several cardiovascular diseases (CVDs)
including atherosclerosis, hypertension, myocardial infarction.40,41 Inflammasomes
also play a role during granulopoiesis aiding in myeloid lineage specification.
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Specifically, caspase-1 cleaves transcription factor GATA1, thus increasing the
production of neutrophils. Furthermore. IL-1β activates a PU.1- dependent gene
program that stimulates granulocyte lineage differentiation.42
TLRs in the heart
TLRs have been shown to play an important role in immune signaling in the heart
after damage. In the heart, TLR2, 3, 4 and 6 have been identified in cardiomyocytes
while TLR1 through 6 have been found in smooth muscle and endothelial cells

43.

In

particular TLR2 and TLR4 are important in inflammation of the heart. TLR4-deficient
mice have a weakened inflammatory response characterized by reduced levels of NFκβ and pro-inflammatory cytokines TNFα and IL1β, smaller infarctions, and fewer
cardiac infiltrations44. TLR2 activation in the heart has been shown to upregulate proinflammatory cytokines. At first this is beneficial as it leads to mitochondrial
stabilization; however, sustained TLR signaling leads to activation and recruitment of
leukocytes to the cardiac microenvironment, which in turn leads to tissue destruction 37.
Inflammatory cytokines released in the cardiac microenvironment following
damage
Inflammatory cytokines and chemokines play an important role in the
pathogenesis of myocardial dysfunction and cardiac remodeling. These pleiotropic,
multifunctional cytokines are upregulated in response to myocardial injury in patients
following MI.45 The early inflammation phase of remodeling is characterized by release
of TNFα, IL-1α, IL-1β, and IL-18. The next phase is characterized by release of antiinflammatory cytokine such as TGFβ.
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Pro-inflammatory cytokines
High TNFα levels have consistently been documented in experimental models of
heart failure and in patients. This cytokine exerts a negative inotropic action on
cardiomyocytes by disturbing the calcium homeostasis, triggering apoptosis by
activating cell death pathways.45 In fibroblasts, the balance between matrix
metalloproteinases (MMPs) and their inhibitors is affected by TNFα, leading to
extracellular (ECM) destruction.46 In the microvasculature, TNFα modulates
cyclooxygenase-2, which in turn leads to increased expression of intercellular
adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1). This
causes pro-inflammatory immune cells to migrate to and remain in the cardiac
microcirculation, leading to tissue injury and cardiac dysfunction.47
IL-1 has two ligands, IL-1α and IL-1β, both of which have high sequence homology.
Infarcted hearts have been shown to have increased levels of IL-1 family proteins. It
has been observed that IL-1 has a pro-apoptotic and hypertrophic effect on
cardiomyocytes, which can depress cardiac contractility. IL-1, along with TNFα,
causes cardiomyocyte apoptosis via pathways involving nitric oxide (NO) and by
upregulating Bax, Bak, and caspase-3. In addition, IL-1 has been shown to promote
expression of cardiac fibroblast MMP-3, MMP-8, MMP-9 while downregulating
expression of their inhibitors TIMP-2 and TIMP-4 which could lead to degradation of
ECM and is detrimental to heart tissue.48
Anti-inflammatory cytokines
TGFβ is crucial in cardiac fibrosis and remodeling. TGFβ works by binding to
Ser/Thr kinase receptors- TGFβ receptors type I (TGFβRI) and type II (TGFβRII) on
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the surface of cells. Macrophages that infiltrate following myocardial injury have been
observed to release TGFβ in significant quantities. Once released, TGFβ induces
expression of genes that promote and increase ECM production which in turn
suppresses MMP expression and enhances cardiac repair. Additionally, TGFβ binds
to its type I and II receptors and initiates SMAD signaling. This signaling sets into
motion the transformation of fibroblasts to myofibroblasts and eventually ECM
deposition in a cyclical manner. TGFβ can also contribute to fibroblast differentiation
by combining with other pro-inflammatory cytokines to promote endothelial to
mesenchymal differentiation.49
Neutrophils in Heart Damage
Introduction to Neutrophils
Neutrophils are the most abundant granulocytic leukocytes in human peripheral
blood (50-70%). These cells are an essential part of the innate immune system and
help with host defense and inflammation resolution. They are among the shortestlived cells and require continuous replacement from the bone marrow. Neutrophils are
generated by a process known as granulopoiesis. This starts with a granulomonocytic
progenitor that goes through maturation stages from myeloblast to promyelocyte to
myelocyte and then a mature neutrophil. These stages are regulated by the cytokine
G-CSF, which also promotes the circulation of neutrophils by disturbing the CXCR4CXCL12 interaction that helps keep neutrophils in the bone marrow. G-CSF causes
release of neutrophils by reducing expression of CXCL12 on stromal cells in the bone
marrow and CXCR4 on the neutrophils.50 Once tissue damage occurs, and
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inflammatory stimuli and chemokines are released, neutrophils home into these
signals by leaving the circulation and migrating to the site of damage.
Neutrophil Elastase
Neutrophil elastase (NE) is a 29 kDa serine protease from the chymotrypsin family
found in the primary granules of neutrophils. NE activity depends upon a catalytic triad
comprising aspartate, histidine, and serine residues that are separated in primary
granules but come together at the enzyme’s active site in the tertiary structure.
Primarily, NE is active in neutrophils’ response against bacteria, but it has also been
known to cause ECM destruction. In the granules, an acidic milieu protects the cells
from proteolytic activity. Upon activation of neutrophils, fusion between granules and
cytoplasmic

phagosomes

occurs

causing

alkalosis

which

further

triggers

degranulation. NE is liberated into extracellular space in both free and membrane
bound forms.51
NE can target ECM, cell surface ligands, proteins and adhesion molecules. NE can
degrade matrix proteins, including collagen, fibronectin, proteoglycans, heparin and
fibrin. NE also has the ability to evade tissue anti-proteases in the extracellular
environment.52
Neutrophils in CVDs
Neutrophils play a detrimental role in acute MI and neutrophil count correlates
with infarct size, , and heart failure development.53 Neutrophils have also been shown
to be involved in atherosclerosis, thrombosis, and acute coronary syndrome.
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Atherosclerosis is one of the most common causes of MI leading to death. Neutrophils
have been shown to promote the initiation of atherosclerosis by dysregulating vascular
endothelial cells. Also, increased neutrophil counts have been observed in human
atheroma specimens.53 In animal models with atherosclerotic plaques, activated
macrophages

produce

chemokines

to

attract

neutrophils.

The

neutrophil

transmigration is mediated by oxidized low-density lipoproteins via an increase in
endothelial contractility and upregulation of ICAM-1.54 Depletion of neutrophils
reduced atherogenesis. In atherosclerotic lesions, neutrophils release CAMP and
AZU1, which recruit inflammatory monocytes and help upregulate the expression of
adhesion molecules on the surface of endothelial cells, regulating the endothelial cell
layer permeability.42,55

Myeloperoxidase released by neutrophils catalyze the

conversion of hydrogen peroxide to hypochlorous acid, which produces toxic
chloramines that can alter lipoprotein function. Neutrophils also release reactive
oxygen species (ROS), which contribute to plaque vulnerability by oxidizing LDL and
recruiting additional neutrophils.56 Further, study suggests that neutrophils colocalizes with TLR-2 expressing atherosclerotic plaques on endothelial cells. TLR-2
activation on endothelial cells leads to cell stress and apoptosis. This effect is
substantially enhanced by adhesion of neutrophils to endothelial cells. This in turn
correlates with an increased number of luminal apoptotic endothelial cells in
atherosclerotic lesions.42
In MI, neutrophils can exacerbate damage and increase infarct size. Neutrophils
infiltrate at the ischemic border zone and release ROS, which then leads to acute
inflammation and cardiomyocyte apoptosis, leading to destruction of cardiac tissue
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and ultimately impaired heart function. Additionally, release of myeloperoxidase into
extracellular space causes the generation of cytotoxic aldehydes, oxidative stress,
and activation of enzymes that degrade the ECM, leading to impairment in remodeling.
During acute MI, neutrophils release Ca2+ binding proteins S100A8/A9 that primes the
NLRP3 inflammasome to release IL-1β, which stimulates granulopoiesis in the bone
marrow. This leads to accumulation of neutrophils in the infarcted heart, adverse
remodeling, and heart failure.57

Anti-inflammatory strategies have focused on

inhibiting cardiac neutrophil recruitment. Brahma related gene 1(BRG1) is crucial in
mediating neutrophils’ adhesion to the endothelium infiltration of the infarct. 58 When
BRG1 was deleted, reduced infarct size, less fibrosis, and recovery of cardiac function
were reported. Additionally, obstructing the interaction between CC motif chemokine
5 (CCL5) and CXC motif chemokine receptor 4 (CXCR4) in MI shrank infarct size,
conserved heart function and was related to reduced presence of neutrophils and the
formation of neutrophil extracellular traps.59 A study conducted in a mouse model of
MI found that starting 3 days after MI, two populations of neutrophils were found in the
heart: SiglecFhi and a SiglecFlow. SiglecFlow represented young blood neutrophils while
SiglecFhi shared characteristics of aged neutrophils (i.e low CD62L, high CXCR4,
expression of specific transcripts, enrichment of ribosomal protein encoding genes).
The SiglecFhi population was also seen to express high surface ICAM1 expression.
As a result, these subsets have different functional capacities. The SiglecFhi
population was shown to have higher phagocytic capacity and higher ROS production
than the SiglecFlow population and this was detrimental to cardiac remodeling.60
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Neutrophil elastase in CVDs
As discussed previously, NE is in the primary granules of neutrophils and is
released during degranulation. Continuous NE secretion can cause excessive tissue
destruction. NE has also been implicated in arthritis, respiratory, and cardiovascular
diseases. Patients with acute MI have elevated level of NE in plasma. NE degrades
elastin, collagen, and fibrinogen, which can lead to damage following MI. Additionally,
NE induces IL-6 release which leads to impairment of cardiac contractility. 61
Investigations in NE

-/-

mice confirmed that NE was responsible for promoting

excessive inflammation and activating proinflammatory cytokines that contributed to
the cardiac damage following MI.62 NE enhanced myocardial injury by suppressing
the PI3K/AKT pathway. Insulin driven AKT signaling is critical in preventing
apoptosis.63 NE can enter intracellular space and mediate degradation of the insulin
receptor substrate protein, which in turn prevents AKT activation and protection
against apoptosis. In NE-/- mice, AKT signaling was activated and cardiomyocytes
were protected from apoptosis. In this study a pharmacological inhibitor of NE,
silvestat, was found to improve survival and cardiac function after MI. 62
In a study conducted in patients with type II diabetes and MI, there were elevated
levels of NE and neutrophil in atherosclerotic plaques. Additionally, an association
between high NE and MI severity was observed.64 This study showed that higher NE
was detected in detached emboli of atherosclerotic plaques, contributing to plaque
instability.64 NE has also been found to mediate a chronic inflammatory state by
activation of pro-form of TNF and IL-1β, PAR2, and phospholipase C, leading to
translocation of NF-κβ and activation of that signaling pathway.65,66 NE can also lead
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to pro-apoptotic signaling by endothelial cells via ERK, JNK, and p38 MAPK which
can lead to apoptosis of cells.67
Macrophages in CVD:
While neutrophils form an essential part of the early innate immune response in
heart damage the role of macrophages too needs to be discussed in adult mouse
heart. Resident cardiac macrophages form 6-8% of the non-cardiomyocyte
population. The origin of these macrophages is thought to be diverse: primitive yolk
sac-derived, fetal monocyte-derived and adult monocyte-derived. Studies have shown
that neonatal mouse heart contains one macrophage population (MHCIIlow CCR2−)
and one monocyte (MHCIIlow CCR2+) subset, the adult heart contains two different
resident CMs subsets (MHCIIlow CCR− and MHCII high CCR2−). In steady state adult
mouse heart contains embryonic resident CCR2− MHCIIlow macrophages with
reparative function. These CCR2− macrophages are lost within infarcted myocardium,
reduction by 60% almost 2 days after infarction

68.

While neutrophils are the predominant early immune cells in heart post damage,
monocytes/macrophages are the predominant immune cell after (2-5d post injury). It
has been observed that after MI monocytes and macrophages transit from a proinflammatory phase to an anti-inflammatory phase. The main function of these
monocytes and macrophages is to remove debris, myocytes and apoptotic neutrophils
to prepare for tissue regeneration. The heart becomes rapidly infiltrated with Ly6C hi
monocytes that differentiate into M1(pro-inflammatory) macrophages. The numbers
of these monocytes peak around day 3 after infarction 69. These macrophages engulf
cellular debris, degrade ECM and secrete pro-inflammatory cytokines such as TNF-α,
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IL-1β and IL-6. However, it has been shown that M1-like macrophages contributed to
myocardial injury by secreting pro-inflammatory exosomes and miRNAs which
inhibited cardiac healing and angiogenesis. Additionally, macrophages have PRRs
that can detect DAMPs. It has been observed that MI causes the release of danger
signals such as double stranded DNA from dying cells that can be detected by
macrophages. By day 4-7 after damage Ly6Clow monocytes were recruited to the
infarcted myocardium. These Ly6Clow monocytes give rise to M2 macrophages which
secrete IL-10 to suppress inflammation and initiate ECM remodeling and angiogenesis
70,71.

This leads to activation of transcription factor IRF3 (interferon regulatory factor 3)
and subsequent induction of type I interferon production that is detrimental to the
heart. In fact, reduced post MI IRF3-dependent signaling reduced cardiac
inflammation and improved cardiac function and survival

72.

In observational studies in mice and humans it has been seen that there is a
correlation between classical monocytosis and degree of LV dysfunction after MI. In
a mouse model with a chronically expanded pool of circulating Ly6Chi monocytes there
was an increased infiltration of these monocytes and reduced EF following coronary
artery ligation 73. In a study in patients with ST-segment elevation there was a negative
correlation between peripheral blood monocytosis and ventricular function 74. Another
study

showed

corroboration

between

high

levels

of

classical

monocytes(CD14+CD62L+ ) and greater infarct size and systolic LV dysfunction at 4
month follow-up after ST-segment elevation MI 75,76.
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Macrophage recruitment via stress signals released by cardiomyocytes have also
been found to be a source for myofibroblasts. When macrophages release TGFβ this
provides a signal to the activated fibroblasts to trans-differentiate. TGFβ signaling
occurs within fibroblasts through phosphorylation of SMAD2/3

77.

Myofibroblasts

maintain the structural integrity of myocardium by remodeling ECM scaffold. They are
characterized by an increase in α-SMA (smooth muscle actin). Activated
myofibroblasts secreted elevated levels of collagens and other ECM proteins to
prevent wall rupture and myocardial dysfunction. Excess deposition of these ECM
proteins and collagens leads to ventricular stiffness and dysfunction

68.

This process

is called fibrosis. Other cell types such as endothelial cells have also been described
as a source for myofibroblasts via endothelial-mesenchymal transition. Pericytes also
contribute to the fibrotic process by converting to activated myofibroblasts

78.

Immune system in Dox-induced cardiotoxicity
Although studies have demonstrated the critical role of the innate immune system
in heart, the role of innate immunity system in Dox-induced cardiotoxicity has not been
assessed in great detail. The limited studies done in this field have identified some
key components of the innate immune system that contributed to acute Dox-induced
heart damage. Here we discuss the role of immune cells and cytokines in context of
Dox-induced cardiotoxicity
Cytokines and chemokines
Several cytokines and chemokines have been targeted with respect to Doxinduced cardiotoxicity.
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In one study IFN-γ was implicated in Dox-induced cardiotoxicity.79 IFN-γ was shown
to reprogram lipid metabolism and sensitize cardiomyocytes to cardiotoxicity which
worsened heart function. Cardiomyocytes need fatty acids to develop respiratory
capacity and impeding oxidation will interfere with that process. AMPK signaling
enhances fatty acid oxidation and helps regulate the respiratory capacity of
cardiomyocytes. It was observed that with Dox treatment, IFN- γ interfered with AMPK
signaling by the suppression of the AMPK/ACC axis in a p38-dependent pathway
which enhanced the Dox-induced cardiotoxicity.80 Importantly, antibody treatment
against IFN-γ improved the heart function in mice. This demonstrated that inhibiting
IFN-γ could mitigate new as well as previously established Dox-induced cardiotoxicity.
The investigators also found that IFN-γ inhibition had no effect on the therapeutic
efficacy of Dox in mice with tumors.81
A study in breast cancer patients receiving Dox found that the plasma levels of
cytokines CCL27 and MIF were elevated after two cycles of Dox. 82 CCL27 is
associated with homing of T lymphocytes to sites of inflammation while MIF is a crucial
cytokine involved in acute and chronic inflammatory response. MIF has been found to
play a role in maintaining cardiac homeostasis and found to be elevated in MI,
atherosclerosis, and other disorders.83 MIF could play a role in protecting against
cardiotoxicity by attenuating the loss of autophagy and ATP availability in the heart
leading to maintenance of cardiac homeostasis.84 CCL23, also called macrophage
inflammatory protein 3, was also found to be elevated after each cycle. This cytokine
has a suppressive effect on hematopoietic progenitor cells. Previous studies have
shown an association between high levels of CCL23 and coronary atherosclerosis.82
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Another study, conducted in HER2+ breast cancer patients receiving anthracycline
revealed a significant increase in CXCL10 levels from baseline to post-anthracycline
and post-trastuzumab treatment. This increase correlated with a decline in global
longitudinal

strain.79

CXCL10

has

several

roles,

including

serving

as

a

chemoattractant for monocytes, macrophages, T cells, and NK cells and promoting Tcell adhesion to endothelial cells, thereby leading to significant infiltration of these
immune cells during cardiac remodeling.85
When aortas of mice treated with Doxorubicin were studied, there was a higher
concentration of pro-inflammatory mediators such as IL-1β, IL-2, IL-6 and TNFα. TNFα
levels had the highest elevation which was associated with intrinsic wall stiffness that
was prevented by inhibition of TNFα.86
A study conducted in breast cancer patients who received Dox found that compared
to baseline the levels of IL-10 were significantly increased 7 days after therapy
completion in patients with cardiotoxicity. Increased levels of plasma NT-proBNP (a
marker for cardiac injury) correlated with the increased IL-10 levels in patients with
cardiotoxicity. IL-10 levels also were positively correlated with IL-1β in the patients
with cardiotoxicity, even though IL-10 is an immunosuppressive cytokine.87
TLRs
TLRs have also been found to be important as part of the innate immune response
to Dox-induced cardiotoxicity.88 TLR5 was found to be significantly elevated in hearts
of mice treated with Dox. TLR5 deficiency led to reduced NOX2 levels in particular.
NOX2 is an isoform of NADPH oxidase, a primary source of ROS in the heart. This
was important as the investigators demonstrated that TLR5 activated NOX2 through
38

Syk phosphorylation.

88

TLR5 deficiency attenuated this effect. Dox was found to

activate the p38 signaling pathway, which led to apoptosis of cardiomyocytes. This
p38 pathway was NOX2 dependent and hence activated by ROS. This pathway was
also inhibited in TLR5 deficient mice.89, 88 TLR5 deficiency led to lower TNFα and IL1β mRNA levels and NF-κβ translocation was also inhibited in these mice and this led
to improvements in heart function and less myofibrillar disruption in mice treated with
Dox..88
In a study conducted in mice with TLR9 deficiency that had been treated with Dox it
was found that cardiac function, myocardial fibrosis and markers for myocardial
damage were all reduced as compared to mice treated with Dox alone. TUNEL
staining further revealed that in TLR9 KO mice with Dox treatment there was a
significantly reduced number of apoptotic cardiomyocytes and reduced ROS
production compared with wild-type (WT) mice with Dox treatment. Furthermore, it
was found that TLR9 promoted the oxidative stress and apoptosis through p38 MAPKdependent autophagy leading to death of cardiac cells.90
Another TLR whose relationship to Dox-induced cardiotoxicity has been studied in
mice is TLR2. TLR2- KO mice showed less NF-κβ activation, along with a lower
production of pro-inflammatory cytokines (TNFα and IL-6), compared with WT mice.
The TLR2-KO mice had higher survival rates than WT mice after Dox treatment.
Furthermore, fewer TUNEL-positive cells were found in the myocardium, and
caspase-3 activation was suppressed in the TLR2 KO mice with Dox treatment. 91 In
a study measuring inflammatory biomarkers in patients with heart failure, expression
levels of TLR2 increased in patients in both the Dox group without heart failure and
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the Dox plus heart failure group.92 In another study evaluating the anti-inflammatory
role of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor that
is used to reduce the risk of cardiovascular death for patients with heart failure, with
respect to TLR2 deficiency, it was found that administration of the drug improved heart
function and prevented cardiac fibrosis after Dox treatment. In addition, LCZ696 also
prevented high TNFα expression. In TLR2-KO mice, similar results were observed,
suggesting a connection between drug action and TLR2. Further studies found that
LCZ696 attenuated the formation of the TLR2-MyD88 complex and this in turn
alleviated the negative effects of Dox, as Dox promotes the formation of the TLR2MyD88 complex.93
TLR4, a receptor of endotoxin, has also been shown to contribute to cardiac
inflammation in Dox-induced cardiotoxicity. TLR4-KO mice had improved LV function
and a reduction in cardiac ET-1 which contributes to heart failure. Additionally, when
lipid peroxidation and nitrotyrosine were examined as markers of oxidative stress in
TLR4-KO mice treated with Dox, there was significantly reduced oxidative stress. This
study in an animal model of ischemia/reperfusion also suggested that TLR4
contributed to the development of oxidative stress. Furthermore, it was observed that
infiltration of lymphocytes, monocytes, and macrophages was reduced in the TLR4KO mice treated with Dox compared to Dox-treated control mice.

94

Upregulation of

the pro-apoptotic protein Bax, was observed in WT Dox-treated mice which was not
seen in the TLR4-KO mice. These findings were confirmed by TUNEL assay where
reduced apoptotic cells were seen in the TLR4-KO group. This study also found a
significant upregulation of Bcl-2, an anti-apoptotic protein, in TLR4-KO mice with Dox
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treatment as compared to TLR4-KO mice. In a mouse study, downregulation of the
GATA-4 pathway was seen in Dox-induced cardiomyopathy, down regulation of this
pathway is known to promote Dox-induced cardiotoxicity. However, in TLR4-KO mice
this down-regulation did not occur, nor did the disease.94 Another finding that supports
the importance of TLR4 in Dox-induced inflammation was that TLR4 expression was
increased in macrophages following Dox treatment. When TLR4 was suppressed or
depleted by injecting TAK-242 or using TLR4lps-del mice lower myofibrillar disruption as
compared to Dox groups was observed.95
Signaling pathways
One signaling pathway that has been implicated in dox-induced cardiotoxicity is
the cGAS-STING pathway. It has been observed that cGAS-STING dependent type I
IFN signaling which is induced by DNA damage is responsible for driving inflammation
in the cardiac microenvironment leading to pathological cardiac processes. In Stinggt/gt
mice which had loss of cGAS-STING signaling, cardiac function was rescued even
after a five-dose regimen of Dox. An inhibitor of CGAS-STING signaling, H-151,
prevented the decline in ejection fraction and the ventricular dilation that occurs via
the increase in LV end diastolic volume 79.
Innate Immune Cells
The role of innate immune cells, especially neutrophils, has been discussed about
in great detail in CVDs. However, the role of these immune cells in Dox-induced
cardiotoxicity needs to be looked at in greater detail.
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Macrophages
In the case of macrophages in Dox-induced cardiotoxicity, most studies have
focused on polarization of macrophages in the cardiac micro-environment. In a study
conducted in mice evaluating the effects of Latifolin in Dox-induced cardiotoxicity it
was found that Dox increased the expression of markers for M1 macrophages(proinflammatory) while latifolin, a new flavonoid, attenuated this effect by increasing the
expression of M2(anti-inflammatory) markers. The increase in M1 markers in the Dox
group was accompanied by increase in release of inflammatory cytokines such as IL6, TNFα and IL-1β which latifolin was also able to prevent

96.

In a similar study

conducted using glabridin, an isoflavone, it was found that glabridin modulated colonic
macrophage populations skewing it more towards an M2 like phenotype. It was also
observed that this modulation by gut microbiota prevented cardiomyocyte apoptosis
97.

In another study conducted to evaluate the effect of adoptive transfer of M2
macrophages in Dox-induced cardiotoxicity it was found that M2 macrophages
improved left ventricular function post Dox treatment as compared to Dox treatment
alone. Additionally, Dox caused increase in cardiomyocyte vacuoles and interstitial
fibrosis and decrease in cardiomyocyte size that was counteracted by M2 macrophage
transfer. Levels of c-caspase 3 and TUNEL positive cells were also increased in Dox
treatment alone mice. However, in mice with M2 macrophages and Dox treatment this
effect was reversed, and this was found to be independent of the AKT and ERK
pathway.

This

study

also

indicated

that
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mitochondria

internalization

into

cardiomyocytes in the presence of M2 macrophages alleviated the cell stress induced
by Dox 98.
In a study conducted in mice with IL-22 knockout it was found that cardiac
oxidative stress was reduced in these mice and phosphorylation of p38 was also
decreased in cardiac macrophages. This decrease in p38 led to lower cardiomyocyte
apoptosis. Further studies showed that IL-22 knockout reduced phosphorylation of
p65 that maybe downstream of p38 and could regulate macrophage differentiation.
The deletion of IL-22 also was found to alleviate the imbalance between M1 and M2
macrophages 99.
Invariant natural killer T cells
Invariant natural killer T-cells (iNKT) are a subset of T-lymphocytes that express
properties of both T cells and natural killer cells. Studies have shown that iNKT cells
modulate cardiac tissue inflammation. For example, treatment with alphagalactosylceramide (αGC), an activator of iNKT cells, prevented damage after MI.
Another study looked at these cells in the context of Dox-induced cardiotoxicity and
found that heart function was normal in mice treated with Dox and αGC simultaneously
but not in mice treated with Dox only. Additionally, an analysis for fibrosis found that
there was low collagen deposition in the mice treated with Dox+ αGC compared to
mice with treated with Dox only. A qPCR analysis revealed that M2 macrophage
expression was higher in mice treated with Dox+ αGC mice than in mice with Dox
only.100
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Neutrophils
Neutrophils may also contribute to Dox-induced cardiotoxicity. In one study
examining therapy-related clonal hematopoiesis following anti-tumor agents including
Dox, cardiotoxicity was augmented by the infiltration and activation of neutrophils. In
this study, an elevation of neutrophils was observed in cardiac tissue, which peaked
at 7 days after treatment with single bolus of Dox. When mice were transplanted with
Trp53 heterozygous mutant bone marrow cells to establish a model of clonal
hematopoiesis, neutrophil recruitment was higher in heart tissue compared to mice
transplanted with WT cells post Dox treatment. Furthermore, when these Trp53
heterozygous deficient neutrophils were analyzed for gene expression, these
neutrophils were enriched for genes related to the inflammasome pathway (i.e. Nlrp1b,
Gbp5, Il18) and chemokines (e.g. Ccl25, Ccrl2 and Cxcl1). When neutrophils were
depleted in the mice with Trp53-deficient cells an amelioration of echocardiographic
parameters including fractional shortening was observed after Dox treatment
indicating that neutrophil involvement is crucial for the detrimental effects of Dox. 101
In another study conducted in breast cancer patients receiving anthracyclines high
level of plasma neutrophil extracellular traps was seen to be associated with Doxinduced cardiotoxicity.102
However more studies need to be done to examine this crucial component of the
innate immune system in Dox-induced cardiotoxicity as there is increasing evidence
implicating neutrophils in Dox-induced cardiotoxicity.
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Chapter Three: The role of neutrophils in Dox-induced cardiotoxicity
This chapter is based upon “ Bhagat A, Shrestha P, Jeyabal P, Peng Z, Watowich
SS, Kleinerman ES. Doxorubicin-induced cardiotoxicity is mediated by neutrophils
through release of neutrophil elastase. Front Oncol. 2022 Aug 10;12:947604” as a
part of CC-BY Creative Commons attribution license.

Introduction:

The mechanisms that contribute to Dox-induced acute and late cardiotoxicity are
not completely understood. One understudied area is whether acute inflammation and
the innate immune response contributes to Dox-induced cardiotoxicity. Other models
of heart damage, such as myocardial infarction, showed that an inflammatory
component was induced in response to damaged cardiomyocytes which included
release of damage associated molecular patterns (DAMPs) that are detected by
pattern recognition receptors (PRRs)

103.

Neutrophils have been shown to play an

important role in cardiac healing by clearing debris and necrotic tissue and inducing
the polarization of monocytes/macrophages to the M2 phenotype- a critical process
to healing. However, neutrophil persistence can be detrimental facilitating myocardial
damage 42.

Neutrophils are the most abundant leukocytes and are the first to be recruited to
an inflammatory site. Neutrophils act by releasing reactive oxygen species, a
demonstrated mechanism of Dox-induced cardiotoxicity, as well as serine proteases.
One such serine protease is neutrophil elastase (NE), which is secreted extracellularly
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from azurophilic granules upon activation

50.

NE plays a crucial role in neutrophil

mediated killing of bacteria. However, NE is also involved in tissue destruction and
inflammation. NE release may therefore contribute to the cardiac tissue damage
following Dox therapy. Studies have shown that NE has the capacity to degrade
elastin, collagen and fibrinogen, thereby contributing to damage after myocardial
infarction (MI). It has also been shown that NE deficiency improved survival and
cardiac function post-MI

62.

Neutrophils and NE-mediated tissue damage have been

shown to play a role in arthritis and respiratory diseases

104,105.

However, whether

neutrophils and NE contribute to Dox-induced acute cardiac damage has not been
determined.

Here, we investigated whether neutrophils and NE contribute to cardiac damage
and the acute and late cardiotoxicity that develops following Dox therapy.

Results:

Effect of Dox therapy on cardiac function and neutrophil infiltration:

Our juvenile mouse cardiotoxicity model

33,34

was used to investigate whether

neutrophils contribute to Dox-induced cardiac damage. Echocardiograms showed a
decrease in EF, FS and an increase in LVID(s) 24 h after Dox therapy (Figures 1a and
1b). Heart tissue analyzed at the time by flow cytometry showed that neutrophils
(CD11b+Ly6G+ cells, gated from the CD45+ population) were significantly elevated in
the hearts of Dox-treated mice compared to controls (Figure 1c, p < 0.01). This finding
was further validated by immunofluorescence staining using anti-Ly6G antibody
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(Figure 1d). Having demonstrated that neutrophils are increased 24 h after Dox
treatment, we next determined whether neutrophils persisted in the heart. Mice were
treated with Dox twice a week for 2 weeks and then evaluated for cardiac neutrophil
infiltration 11 weeks after the therapy. No differences were observed in neutrophil
numbers (CD11b+Ly6G+) between the hearts of Dox-treated and control mice 11
weeks after therapy (p=0.52) (Fig 1e). These data indicate that Dox therapy induced
an acute increase in cardiac neutrophils, which was not sustained.

CXCL1 is involved in neutrophil recruitment. To determine if Dox-induced the
upregulation of CXCL-1 in the heart tissue, CXCL1 mRNA was quantified and found
to be significantly upregulated in the cardiac tissue 24 h after Dox therapy (Figure 2,
p<0.05).
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Figure 1: Effect of Doxorubicin (DOX) on heart function and neutrophil infiltration 24
h after therapy. a) Ejection fraction (EF) and fractional shortening (FS) in mice were
quantified by echocardiography 24 h after treatment with DOX or control phosphatebuffered saline (PBS); b) Left ventricular internal dimension was measured in systole
(LVID, s). Data are presented as mean ± SEM, n=5 each, p<0.05, a Mann-Whitney Utest was used to compare two groups.; c) Infiltration of neutrophils (CD11b + Ly6G+
cells) in hearts of mice treated with DOX or control phosphate-buffered saline(PBS)
was quantified by flow cytometry 24 h after therapy; d) Infiltration of neutrophils in
hearts (Ly6G+) was quantified by immunofluorescence staining 24 h after therapy; e)
Infiltration of neutrophils (CD11b+ Ly6G+) in hearts was quantified by flow cytometry
11 weeks after therapy. Data are presented as mean ± SEM, n=5 each, *p<0.05, a
Mann-Whitney U-test was used to compare two groups
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Figure 2: CXCL1 expression in cardiac tissue as quantified by qPCR 24 h after Dox
treatment. Data are presented as mean ± SEM, n=4 each, p<0.05, a Mann-Whitney
U-test was used to compare two groups.
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Effect of neutrophil depletion on acute Dox-induced cardiotoxicity:

We next determined whether depleting neutrophils using an anti-Ly6G antibody
prior to Dox therapy inhibited the Dox-induced decrease in cardiac function as defined
by EF, FS and LVID(s). Using Balb/c mice successful depletion of neutrophils was
confirmed by flow cytometry in peripheral blood mononuclear cells (PBMCs) 24 h after
the antibody treatment (Figure 3a). Twenty-four hours after Dox therapy the EF, FS
and LVID(s) changes described above were seen in the Dox treated mice but not in
the neutrophil-depleted mice (Figure 3b, 3c). Control IgG antibody given prior to Dox
did not prevent Dox-induced cardiotoxicity. The decreases in EF and FS and increase
in LVID(s) in the group treated with Dox and IgG was similar to that of the group treated
with Dox only. Increased neutrophils were detected in heart sections of mice treated
with Dox alone and Dox plus IgG (p<0.01). In contrast, neutrophils were not increased
in hearts from mice treated with the anti-Ly6G antibody compared to control hearts
(Figure 3d).

We previously demonstrated that there were changes in the morphology of the
cardiac vessels 24 hours after Dox therapy

33.

These included a decrease in CD31+

and NG2+ vessels, a decrease in the NG2+ pericyte coverage of the cardiac vessels
and a decrease in the number of open lumen vessels with a diameter over 100 µm
which correlated with a decrease in cardiac blood flow. Similar to our previous report,
here we show that the cardiac vessels from mice treated with Dox alone Or Dox plus
IgG appeared more punctate and collapsed, a sign of decreased pericyte coverage.
There was also a significant decrease in the number of vessels with open lumens
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>100µm. These changes were not seen in the cardiac vessels from neutrophil
depleted mice (Fig 3e). These data indicate that neutrophils contribute to damaging
the cardiac vessels following Dox therapy, which leads to an acute effect on heart
function. Depletion of neutrophils inhibited these Dox-induced structural and functional
changes in heart.
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Figure 3: Effect of neutrophil depletion on heart function and vascular morphology 24
h after therapy. a) Depletion of neutrophils was quantified by flow cytometry as
described in Figure 1 b and c; b) In mice with control phosphate-buffered saline(PBS),
doxorubicin(DOX), DOX plus control IgG, or DOX plus anti-Ly6G antibody, ejection
fraction (EF), fractional shortening (FS) were quantified; c) Left ventricular internal
dimension in systole (LVID(s)) were quantified; d) Representative images of
neutrophils (CD11b+ Ly6G+) in the hearts of mice treated with control phosphatebuffered saline(PBS), doxorubicin(DOX), DOX plus control IgG, or DOX plus antiLy6G; e) Representative images of NG2+ and CD31+ vessels. Results are presented
as mean ± SEM, n=5 each, *p<0.05, one-way ANOVA analysis with Tukey
comparison was used to compare the groups.
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Effect of neutrophil depletion on late Dox-induced cardiotoxicity:

To determine whether neutrophil depletion decreased late cardiotoxicity,
neutrophils were depleted as described above and mice were treated with Dox. Heart
function was then monitored for 10 weeks after therapy. There was a continuous
decline in EF and FS in Dox-treated mice (p<0.0001). In contrast, no change was seen
in the neutrophil depleted mice treated with Dox (Figure 4a, p=0.3643). Additionally,
LVID was increased in Dox and Dox plus IgG-treated mice compared to control mice
10 weeks after therapy. This was not seen in the neutrophil-depleted mice (Figure 4b).
Ten weeks after therapy, the compromised vascular structures remained in the hearts
from Dox and Dox plus IgG-treated mice, as defined by a decrease in CD31+ vessels
and NG2+ vessels. By contrast, there remained, no significant decrease or difference
in CD31+ or NG2+ vessels in hearts from neutrophil-depleted mice (Figure 4c).

We previously showed that while no cardiac fibrosis was seen 24 h after Dox
treatment, there was significant cardiac fibrosis (collagen formation) 10-12 weeks after
therapy 33. To determine whether neutrophil depletion impacted Dox-induced collagen
formation, we performed Masson Trichrome staining 10 weeks after therapy. There
was a significant increase in collagen in hearts from Dox-treated mice (p= 0.0015) but
not in the hearts from neutrophil-depleted mice treated with Dox (Figure 4d, p=0.07).
Macrophages have been shown to contribute to cardiovascular diseases 106 . We
therefore determined whether our neutrophil depletion protocol was specific for
neutrophils with no impact on macrophage numbers in the heart 24 h following Dox
therapy. CD11b+Ly6Chi+ and CD11b+F4/80+ populations were used to identify and
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quantify pro-inflammatory monocytes and macrophages respectively. Monocyte and
macrophage numbers were similar in the neutrophil- depleted and control mice treated
with Dox (data not shown). This data indicates that early depletion of neutrophils
prevented late stage cardiotoxicity from developing and also prevented excess
collagen deposition. Additionally, we found that depletion of neutrophils did not affect
the level of monocytes and macrophages in the cardiac microenvironment post Dox
treatment.
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Figure 4: Effect of neutrophil depletion on heart function and vascular morphology
10 weeks after therapy. a) In mice treated with control phosphate-buffered
saline(PBS), doxorubicin(DOX), DOX plus control IgG, or DOX plus anti-Ly6G,
ejection

fraction(EF)

and

fractional

shortening(FS)

were

quantified

by

echocardiography and followed for 10 weeks after therapy; b) Left ventricular internal
dimension in systole (LVID(s)) was also quantified 10 weeks after therapy; c)
Representative images and numbers of NG2+ and CD31+ vessels in the hearts of mice
treated with control phosphate-buffered saline (PBS), doxorubicin (DOX), DOX plus
control IgG, or DOX plus anti-Ly6G 10 weeks after therapy; d) Collagen deposition in
the hearts was determined using Masson trichrome staining 10 weeks after therapy
completion. Data are presented as mean ± SEM, n = 5 each, p < 0.05, one-way
ANOVA analysis with Tukey comparison was used to compare the groups.
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Contribution of neutrophil elastase (NE) to acute and late Dox-induced
cardiotoxicity:

Neutrophils release NE following activation. To investigate whether NE was
elevated and contributed to Dox-induced cardiac damage, NE mRNA levels were
quantified in the cardiac tissue of Dox treated and control mice 24 h after therapy.
Higher NE mRNA levels were seen in the hearts from the Dox-treated mice (Fig 5a).
NE-/- mice were used to evaluate the contribution of NE to Dox-induced acute and late
cardiotoxicity. First to confirm that neutrophils from the NE-/- mice have similar
migratory ability to neutrophils from wild type mice we performed an in-vitro transmigration assay using WKYMVm, a chemoattractant for neutrophils. The migratory
function of neutrophils from the NE-/- mice was not significantly different compared to
neutrophils from wild type mice (Figure 6). Next, we confirmed that Dox therapy
induced an increase in cardiac neutrophils 24 h after therapy in these NE -/- mice.
Similar to wild type mice neutrophils were significantly elevated in Dox-treated NE-/mice (Figure 5b, p=0.04). Therefore, the NE knockout did not inhibit neutrophil
migration into the heart 24 h after Dox treatment. To There was a significant decrease
in EF and FS in the Dox-treated wild-type mice but not in the NE-/-treated with Dox.
The EF and FS in Dox-treated NE-/- mice were similar to those of NE-/- control mice
(Figure 5c). Blood vessel morphology (as determined by quantifying the number of
open vessels with diameter >100µm) was also not significantly different in the NE -/control and NE-/- Dox treated mice and there was no decrease in CD31 + and NG2+
vessels (Figure 5d, p=0.0115).
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Figure 5: Effect of neutrophil elastase knockout (NE-/-) on heart function 24 h after
therapy. A) NE as measured by quantitative PCR in hearts of wild-type and NE-/- mice
24

h

after

treatment

with

control

phosphate-buffered

saline(PBS)

or

doxorubicin(DOX); b) Representative images of neutrophils (CD11b+ Ly6G+) 24 h after
therapy; c) Ejection Fraction (EF) and fractional shortening (FS) were quantified by
echocardiography 24 h after therapy; d) Effect of NE knockout on cardiac vessel
morphology 24 h after therapy. Representative images, the number of NG2 + and
CD31+ vessels, and the frequency (%) of vessels > 100µm/hpf 24h after therapy. Data
are presented as mean ± SEM, n = 5 each, p < 0.05, one-way ANOVA analysis with
Tukey comparison was used to compare the groups.
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Figure 6: Neutrophil Transmigration following doxorubicin treatment was quantified
by Incucyte in the presence and absence of a chemoattractant, a Mann-Whitney Utest was used to compare two groups.
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To evaluate the role of NE in the late stage of Dox-induced cardiotoxicity mice
were treated with Dox for 2 weeks, and cardiac function monitored for 12 weeks. There
was a significant decrease in EF and FS in the Dox-treated wild type mice 24 h after
therapy that persisted over 12 weeks. In contrast, no decrease in EF or FS was seen
in the Dox treated NE-/- mice (Figure 7a). Cardiac vascular morphology was also
unchanged in the Dox-treated NE-/- mice (Figure 7b). The number of open vessels
with a diameter >100µm in the NE-/- control and NE-/- Dox treated mice were not
significantly different (Figure 7b). This data indicated that inhibiting or blocking NE
prevented both the acute and late Dox-induced cardiac damage.
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Figure 7: Effect of neutrophil elastase knockout (NE-/-) on heart function and cardiac
vessel morphology 12 weeks after therapy. a) Ejection Fraction (EF) and fractional
shortening (FS) were quantified by echocardiography and followed for 12 weeks after
treatment with control phosphate-buffered saline (PBS) or doxorubicin (DOX) in wildtype and NE-/- mice; b) Representative images of cardiac NG2+ and CD31+ vessels 12
weeks after therapy and frequency (%) vessels with >100µm/hpf. Data are presented
as mean ± SEM, n = 5 each, p < 0.05, one-way ANOVA analysis with Tukey
comparison was used to compare the groups.
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Ogura et al showed that the NE caused cardiomyocyte apoptosis in myocardial
infarction

107.

We wanted to investigate these findings in our context of Dox-induced

cardiotoxicity. TUNEL staining was used to identify apoptotic cells. The number of
TUNEL cells was significantly higher in Dox treated mice as compared to NE -/- mice
(Figure 8). We also found that the TUNEL positive cells were specific to
cardiomyocytes as evidenced by staining with cardiac troponin (Figure 9). Additionally,
we quantified cleaved caspase-3 levels in Dox-treated control and NE-/- mice to
investigate the effect of decreased NE on cardiomyocyte apoptosis after Dox
treatment. Cleaved caspase-3 protein was significantly elevated in the control Dox
treated hearts as compared to the NE-/- Dox treated hearts (Figure 10).
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Figure 8: Effect of neutrophil elastase knockout (NE-/-) on apoptosis in heart tissue
following doxorubicin (Dox) treatment. Representative TUNEL staining images of
heart sections 24 h after Dox treatment; Data are presented as mean ± SEM, n = 5
each, p < 0.05, one-way ANOVA analysis with Tukey comparison was used to
compare the groups.
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Figure 9: Representative TUNEL staining images of heart sections 24 h after Dox
treatment counterstained with CnTI (Cardiac Troponin I).
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Figure 10: Representative images of Western blots for caspase-3, cleaved caspase3 and GAPDH from hearts 24 h after treatment; the protein levels of cleaved caspase3 were quantified using densitometry analysis and normalized to the levels of
caspase-3; Data are presented as mean ± SEM, n=3 each, a Mann-Whitney U-test
was used to compare two groups.
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Having demonstrated that NE contributed to Dox-induced cardiotoxicity we
investigated the therapeutic potential of an NE inhibitor, AZD9668. Here mice were
treated with Dox, AZD9668 or both drugs concurrently. Decreased EF and FS were
seen in the Dox-treated mice but not in mice that received Dox plus AZD9668 (Figure
11). This effect persisted for 12 weeks after Dox treatment had ended indicating that
an NE inhibitor has therapeutic potential to prevent Dox-induced heart damage.

Figure 11: Effect of neutrophil elastase (NE) inhibitor on heart tissue following
doxorubicin (DOX) treatment. Ejection fraction (EF) and fractional shortening (FS)
were quantified by echocardiography up to 12 weeks after therapy. Data are
presented as mean ± SEM, n = 5 each, p < 0.05, one-way ANOVA analysis with Tukey
comparison was used to compare the groups.
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Discussion:

Dox continues to be an integral part of treatment for pediatric and adolescent and
young adult patients (AYA) with sarcoma due to the lack of new effective targeted
therapies, including immunotherapies. Unfortunately, Dox causes acute damage to
the heart resulting in late cardiac morbidities which range from changes in myocardial
structure and function, to severe cardiomyopathy, valvular disease and congestive HF
in long-term survivors. These cardiac morbidities compromise quality of life (QOL) and
longevity and may result in a need for cardiac transplant

108,109.

Indeed, Dox-induced

cardiotoxicity is the second leading cause of death in childhood and AYA cancer
survivors 110,111. Therefore, strategies to limit the acute heart damage caused by Dox
are expected to result in lower cardiac morbidities, improved longevity and better QOL.
Identifying effective interventions requires an understanding of the multiple
mechanisms that contribute to Dox-induced cardiotoxicity 112 .

Here we demonstrated for the first time that Dox therapy induced the acute
infiltration of neutrophils into the heart (as quantified by flow cytometry and
immunofluorescence staining. This was accompanied by an acute decline in cardiac
function, (defined by decreased in EF and FS and increased LVID), an alteration in
cardiac vascular morphology, and a decrease in the number of cardiac vessels with
open lumens. The increase in cardiac neutrophils did not persist. No differences in
neutrophil numbers in the heart were seen 4-11 weeks after therapy in Dox-treated
versus control mice. This is in accordance with previous studies demonstrating that
neutrophil infiltration was short lived, peaked early but dissipated at later time points
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104.

Despite the normalization of neutrophil numbers, the decreased cardiac function

persisted for 2-12 weeks after therapy.

The importance of neutrophils and NE in the acute Dox-induced cardiotoxicity
process was confirmed using neutrophil-depletion techniques and NE-knockout mice.
We confirmed that neutrophil depletion using anti-Ly6G was successful and that this
resulted in no increase in cardiac neutrophils 24h following Dox therapy. Our data
showed that Dox-induced acute cardiotoxicity was not seen in either neutrophildepleted mice or NE-/- mice. Under these conditions EF, FS, LVID(s) and vascular
morphology were unchanged 24 h after Dox therapy. We also confirmed that the
increase in neutrophil infiltration following Dox therapy in the NE -/- mice was not
significantly different than that seen in wild-type mice, indicating that the absence of
NE did not interfere with the neutrophils’ ability to migrate into the heart. Similar to our
results, Hirche et al showed that during infection the neutrophil recruitment to sites of
inflammation were not hindered in elastase knockout mice

113.

Their data showed no

differences in the ability of WT and NE−/− neutrophils to migrate to sites of
inflammation.

This is in contrast to the findings of Voisin et al where impaired

neutrophil invasion into the heart tissue was seen following ischemia/reperfusion injury
114.

The difference between our findings may be due to the fact that we are

investigating Dox-induced cardiac damage which is not the same as damage induced
by ischemia.

We have previously shown that Dox therapy acutely affected cardiac vascular
structure, morphology and function as defined by decreased pericytes, collapsed
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cardiac vessels, and a decrease in the number of vessels with open lumens, resulting
in decreased cardiac diastolic and systolic blood flow

33,34

. Neutrophil-depleted and

NE-/- mice showed none of these acute changes in vascular structure 24h after Dox
therapy. We interpret this to mean that neutrophil depletion and the absence of NE
prevented acute Dox-Induced vascular damage.

Cardiotoxicity is known to develop in survivors many years after treatment. We
therefore investigated whether neutrophil depletion and NE knockout prevented the
late Dox-induced cardiotoxicity. When we evaluated heart function 10 weeks after
treatment was completed, we observed significant decreases in EF and FS, and an
increase in LVID(s) in the Dox-treated mice. However, as demonstrated in the acute
cardiotoxicity experiments, there was no change in cardiac function in the neutrophil
depleted mice. The vascular changes also were not observed in the neutrophildepleted mice. In addition, there was significant collagen deposition consistent with
the development of cardiac fibrosis in the hearts of the Dox-treated control mice but
not the neutrophil-depleted mice treated with Dox.

Taken together, these data further confirm that neutrophils contribute to the acute
heart damage caused by Dox. This acute damage had a prolonged effect on the heart.
Inhibiting this acute phase prevented the development of late-stage cardiotoxicity. Our
data suggest that neutrophils contribute to both acute and late Dox-induced
cardiotoxicity. Neutrophil depletion had no effect on macrophage infiltration following
Dox therapy. We also demonstrated in the heart tissue that after Dox treatment Dox
there was increased expression of CXCL1, a cytokine involved in neutrophil
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recruitment. These results suggest a direct mechanism by which Dox induces
neutrophil infiltration into the heart.

Previous reports have also shown that neutrophils are recruited to the heart
following cardiac injury such as myocardial infarction. Here damaged cardiomyocytes
act as DAMPs that are detected by PRRs which release cytokines such as CXCL1
that helps recruit neutrophils

103.

Furthermore, when we performed TUNEL assay on

wild-type and NE-/- mice following Dox treatment we observed a significant number of
apoptotic cells in hearts from the wild-type mice but not the NE-/- mice. Taken together,
these results indicate that neutrophils through the release of NE contribute to
cardiotoxicity and that inhibiting NE prevents this cardiotoxicity. To test the therapeutic
potential of targeting NE we administered the NE inhibitor AZD9668 during Dox
treatment. We found that the EF and FS did not change in mice treated with AZD9668
and Dox and more importantly that this protection persisted for up to 12 weeks after
the Dox treatment had been completed. These results suggest that targeting NE
during Dox therapy may decrease acute Dox-induced cardiac damage.

In this study we focused on NE as we have observed higher expression levels of
this enzyme in hearts with Dox. However, the role of other serine proteases that
neutrophils release upon degranulation such as cathepsin G and proteinase 3

115,

may also contribute to Dox-induced cardiotoxicity and should be investigated.
Additionally, we briefly monitored levels of another myeloid cell population,
monocytes/macrophages, in hearts of Dox-treated mice after neutrophil depletion.
Traditionally, macrophages participate in phagocytosis, chemotaxis, secretion and
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antigen presentation for immune defense and tissue healing 116. The plastic nature of
these cells has rendered their exact function in the cardiac microenvironment post
heart damage unclear 117,118. Hence, a deeper look into the role of macrophages with
further characterization of macrophages that are characterized into either
M1(classically activated pro-inflammatory) or M2 (alternately activated antiinflammatory) 119,120 in Dox-induced heart damage needs to be done.

In summary our results show that neutrophils contribute to Dox-induced cardiac
damage, through the release of NE leading to vascular damage and decreased heart
function that persist many weeks after therapy completion. This is the first study of its
kind to demonstrate that neutrophils and neutrophil elastase are involved in Doxinduced cardiotoxicity. In our study we made clear that Dox was causing cardiac cell
death. This cardiac cell death in turn induced the upregulation of chemotactic
cytokines such as CXCL-1 as part of the inflammatory process that is triggered
following cardiotoxicity. This upregulation then led to neutrophil migration into the
damaged heart tissue contributing to additional damage amplifying cardiotoxicity. It is
not our contention that Dox does not control or induce NE directly. Rather that the
tissue damage induced by Dox leads to the initiation of the inflammatory process that
involves neutrophils. When neutrophils migrate into the damaged tissue, NE is
released, and it is this released NE that causes further cardiac damage. Our results
showing that a NE inhibitor mitigates Dox-induced cardiotoxicity supports this
hypothesis. In pre-clinical models in rats, NE inhibitors ablated the ischemia-induced
myocardial damage and coronary endothelial dysfunction

61.

Furthermore in clinical

trials, NE inhibitors have been used to treat cystic fibrosis and chronic obstructive
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pulmonary disease and have been found to be safe and well tolerated and effective in
curbing the excess inflammatory response

121,122.

AZD9668 in particular, has been

used in clinical trials for patients with chronic obstructive airway disease and was
found to have no significant toxicity while showing promising therapeutic potential in
early phase studies

123.

In our cardiotoxicity mouse model, AZD9668 was well

tolerated and effective in inhibiting Dox-induced cardiac damage and in preserving
heart function after Dox therapy. This is a significant finding with translational potential
to decrease the incidence and degree of cardiomyopathies in CCS, which in turn will
impact both QOL and patient longevity, as cardiac disease is the second leading
cause of death in these individuals

124.

Our data supports consideration for the

inclusion of a NE inhibitor with Dox with the goal of preventing Dox-induced acute and
late cardiotoxicity in survivors. NE inhibitors may decrease the acute inflammatory
response induced by Dox preventing cardiomyocyte apoptosis and the late fibrosis
that develops.

Conclusion:

In conclusion we found that neutrophils play an important role in Dox-induced
cardiotoxicity through release of neutrophil elastase. Our finds suggest a new
treatment approach for mitigating this damage during Dox treatment.
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Chapter Four: Global Discussion

Introduction
We have demonstrated the importance of neutrophils in Doxorubicin (Dox)induced cardiotoxicity and a possible therapeutic intervention targeting neutrophils.
However, there are several other questions that arise from this. The roles of
macrophages need to be examined in greater detail. Monocytes/macrophages act in
tandem with neutrophils when it comes to immune responses to tissue injury. We have
generated

some

preliminary data

regarding

macrophages in

Dox-induced

cardiotoxicity that will be discussed below.
Furthermore, we have shown that release of neutrophil elastase and its blockage
has an ameliorative effect. Probing the other serine proteases released from the
azurophilic granules will provide a more thorough understanding of how neutrophils
contribute to Dox-induced cardiotoxicity. Additionally, neutrophils also release reactive
oxygen species (ROS) as a mechanism for microbial killing and formation of neutrophil
extracellular traps (NETs). This could be another avenue for exploration. Additionally,
blocking neutrophil elastase in a tumor bearing mouse model would be important to
determine whether AZD9668 affects efficacy of anti-tumor action of Dox.
While cardiomyocytes form the main component of heart there are other cells that
play important roles in development and response to tissue injury. One such cell
population is cardiac fibroblasts. Previous studies have identified this population to be
vital in the third phase of cardiac remodeling post injury. However, there are other
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studies that have found them to be crucial mediators of innate immune response in
heart. The role of cardiac fibroblasts in Dox-induced cardiotoxicity hasn’t been
examined in great detail. This would be a promising target to look at in future
experiments to further delineate the innate immune response in heart.
Neutrophil Elastase inhibition in a tumor bearing mouse model
In our study we examined the effects of a pharmacological inhibitor of NE on
Dox-induced cardiotoxicity in a non-tumor bearing mouse model. In a future study this
would need to be studied in a tumor bearing mouse model to examine if the NE
inhibitor has any effect on the efficacy of Dox in its anti-tumor action. Our hypothesis
is that AZD9668 would have no effect on Dox’s anti-tumor action due to differences in
mechanism of action of both drugs. Dox acts on tumors by i) intercalation of DNA
strands, ii) topoisomerase suppression and iii) generation of free radical species. In
contrast AZD9668 acts by binding the active site of enzyme and in particular the
catalytic triad of S195, D57 and H102(serine, aspartate and histidine) 125.
Macrophages
Our results showed that neutrophils play an important role in Dox-induced
cardiotoxicity. While these cells are one of the first to infiltrate into infected or damaged
tissue, macrophages also have been shown to play a key role in the acute innate
immune response. Neutrophils have been shown to peak on day 1 post myocardial
infarction

126,

however monocytes aggregate over days. This accumulation occurs in

two waves: first Ly6Chi monocytes (days 1–4 post-MI) and then Ly6Clo monocytes
(days 4–7) 126.
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Ly6Chi monocytes give rise to cardiac macrophages which proliferate and
replenish cardiac resident macrophages lost after myocardial infarction (MI). Cardiac
macrophages release inflammatory mediators promoting local inflammation such as
proteases, reactive oxygen species and inflammatory cytokines like TNFα. These
macrophages are needed for debris clearance and infarct healing. Ly6C hi monocytes
while being crucial to infarct healing can also be detrimental due to excess production
of inflammatory mediators 73. In the second reparative phase that takes place 3 days
after MI the Ly6Chi monocytes differentiate to reparative macrophages that produce
TGFβ, VEGF and IL-10. The release of these factors induces collagen production by
myofibroblasts 127. Excessive collagen deposition however is detrimental and can lead
to fibrosis and compromised heart function due to stiffening of cardiac muscle.
In mice undergoing depletion of macrophages by chlodronate liposomes post
myocardial injury it was observed that there was a reduced removal of necrotic cells,
impaired neovascularization and increase in infarct size. This in turn led to increased
mortality in macrophage depleted mice 128.
ROS
From literature it is known that Dox induces ROS production which can result in
tissue damage. NADPH oxidase, cytochrome P-450 reductase and xanthine oxidase
transform Dox in the form of quinone to semiquinone via one electron reduction of the
quinone moiety in ring C within mitochodria 129. The semiquinone regenerates back to
parental quinone by reacting with oxygen generating superoxide anion further
converting to other ROS species. It is this redox recycling that amplifies production of
free radical species. Endothelial nitric oxide synthase also affects Dox-induced ROS
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production 130. Furthermore, the amount of antioxidant enzymes in cardiac tissue such
as superoxide dismutase and catalase is lower than in other organs making the heart
more susceptible to damage from ROS

131.

Dox also binds to cardiolipin, a

phospholipid component of heart mitochodrial inner membrane
retained in the cardiac cells as doxorubicinol.

132.

Dox is also

In cancer patients receiving Dox

treatment there is a decrease in glutathione suggesting a reduction in antioxidant
status 133.
ROS has also been implicated in modulation of several cellular hypertrophic
pathways including tyrosine kinases (Src and focal adhesion kinase), protein kinase
C (PKC), mitogen activated protein kinases (MAPK; ERK1/2, p38, and JNK),
calcineurin, PI3K/Akt, and NF-κB 134. ROS was also seen to activate apoptosis signalregulating kinase 1, this stimulates p38 and JNK MAPK and NF-κB pathways 135.
Other serine proteases
In our study AZD9668 is specific for neutrophil elastase (NE), but does not inhibit
proteinase 3 or cathepsin G. We demonstrate the importance of NE in Dox-induced
cardiotoxicity; however, it would also be important to examine the roles of both serine
proteases in Dox-induced cardiotoxicity.
Cathepsin G
Another serine protease from the azurophilic granules is cathepsin G. Similar to
neutrophil elastase, cathepsin G has pro-inflammatory properties that play a role in
degradation of extracellular matrix (ECM) components, as well as being a
chemoattractant for leukocytes such as T-cells. It also plays a role in tissue

78

remodeling. Additionally, Cathepsin G has been observed to activate the matrix
metalloproteinase MMP-2 which can induce apoptosis 136. Cathepsin G has also been
found to mediate the regulation of the chemokine RANTES (Regulated upon
Activation, Normal T-cell Expressed and Secreted) which are associated with the
severity of coronary artery disease 137. Additionally, cathepsin G activity also leads to
the generation of angiotensin II which induces the expression of the monocyte
chemoattractant protein-1 (MCP-1) that triggers a profibrotic response by TGF-β1
leading to cardiac fibrosis. Cathepsin G through TGFβ1 formation has also been
observed to initiate calcification of the aortic valve. In human stenotic aortic valve
cathepsin G has been found to be significantly elevated and is associated with
formation of atheroma of carotid artery 138.
Additional studies have shown that cathepsin G triggers a chemotactic response
in absence of myocardial injury. Cathepsin G treated hearts showed increase ECM
degradation. Cathepsin G also induced increase in activity of elastase and chymase
which led to activation of cytokines/chemokines that amplify leukocyte migration to
heart at the time of injury. This induces a cycle with excess neutrophil degranulation
and inhibition of tissue repair 139. This same study also demonstrated the mechanisms
by which cathepsin G provokes the pro-inflammatory response. By inducing cleavage
of IL-1β and IL-18, cathepsin G activates STAT3 and NF-κB signaling pathways to
initiate an inflammatory response 140. Intracardiac administration of cathepsin G in rats
led to early changes in left ventricular (LV) remodeling with a decrease in LV wall
thickness. These rats also had significant ECM degradation and MMP activity. This
study also found that treatment with cathepsin G resulted in more myocyte apoptosis
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139.

These studies have explored the role of cathepsin G with respect to heart diseases

but not Dox-induced cardiotoxicity. Hence it would be important to study this serine
protease in the context of Dox-induced cardiotoxicity.
Proteinase-3
Proteinase-3 is a 29 kDa serine proteinase that is present in azurophilic granules
of neutrophils. It is also present in other specific granules, secretory vesicles and cell
surface. Following translocation to the cell membrane this proteinase is secreted into
extracellular medium by activated neutrophils

141,142.

Proteinase-3 is identified by a

highly conserved catalytic triad (His57, Asp102 and Ser195; using chymotrypsinogen
numbering)

143.

It is initially an inactive precursor that undergoes a two-stage post-

translational modification and becomes active. Proteinase-3 can act in both an
intracellular and extracellular manner. Proteinase-3 has many functions such as
degrading ECM proteins including fibronectin, type IV collagen and laminin

144.

Additionally, it also has a defensive immune role by regulating a number of cellular
processes and can cleave protein to antibacterial peptides and activate proinflammatory cytokines 145.
Several studies have shown a relationship between proteinase-3 and plaque
stabilization in atherosclerotic cardiovascular disease. Proteinase-3 mediates a
chronic inflammatory state by activation of TNF and IL1β 146, activation of proteinaseactivated receptor 2 and phospholipase C that can lead to translocation of NF-κβ 147.
Proteinase-3 has been shown to activate pro-apoptotic signaling of endothelial cells
through multiple pathways: ERK, KNK and p38 MAPK

80

64,67.

Cardiac Fibroblasts
Cardiac fibroblasts form a major part of the cell population in heart. Studies in
rates showed that the heart comprised of 70% myocytes and 30% non-myocytes.
Another study in murine hearts showed that 45% of cells are non-myocytes with a vast
majority being fibroblasts 148. In human hearts the numbers vary. Some reports found
the proportion of fibroblasts to be in the 20-60% range 149. The reason for this disparity
in determining the percentage of fibroblasts is due to the lack of specific markers.
Some of the molecular markers that have been used to identify fibroblasts
include: discoidin receptor 2(DDR2) which can label fibroblasts but not endothelium,
smooth muscle or myocytes. However, not all fibroblasts are DDR2+. Another marker
used to label fibroblasts is Thymocyte 1 (CD90). However, this receptor is also
expressed by immune cells, pericytes and endothelium. Vimentin, an intermediate
filament is also used as a marker for fibroblasts, however it has also been shown to
be expressed on endothelial cells. Fibroblast specific protein 1(FSP1) is considered a
reliable fibroblast marker. However recent findings have shown that it also labels a
subset of immune and endothelial cells 150. For activated fibroblasts αSMA is the most
commonly used marker for activated fibroblasts. Another marker for activated
fibroblasts is periostin as it is expressed developmentally by cardiac fibroblasts but
not by adult fibroblasts

151.

Platelet-derived growth factor receptor α(PDGFRα) was

another marker that was used to identify fibroblasts as it appears to be involved in
formation of CF from the epicardium 152.
The main function of cardiac fibroblasts is to synthesize the collagen rich ECM
network, especially during myocardial remodeling post injury. When fibroblasts react
81

to injury, they transition from a quiescent state to an activated state called
myofibroblasts. This transition post injury is shown to be mediated by multiple
mechanisms including growth factor release in the myocardial environment such as
the cytokines TNFα, TGFβ, PDGFs, cytokines like IL-1, IL-10 and renin angiotensin
system (RAS) proteins. RAS are produced by macrophages and stimulate cardiac
fibrosis by TGFβ signaling pathway. Incorporation of α-SMA into stress fibers is a
characteristic of the myofibroblasts. TGFβ leads to promotion of α-SMA transcription
in fibroblasts by the Smad3 signaling cascade. Active TGFβ can also activate
downstream signaling pathways in the absence of Smad signaling. In fact both Smaddependent and non-Smad pathways have been seen to cause up-regulation of α-SMA
and ECM protein

153.

Myofibroblasts have two functions post injury such as that

caused by MI: secreting ECM protein to replace damaged myocardium and to
stimulate infarct contraction and produce factors to regulate inflammatory response
154.

Some of the ECM proteins that myofibroblasts express include but are not limited

to Type I, III, IV, V and VI collagen, glycoproteins, proteoglycans including fibronectin,
laminin and tenascin

155.

Excessive deposition of collagen causes development of

cardiac fibrosis.
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Figure 12 Graphical Summary
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Chapter Five: Future Directions with preliminary results
As discussed in the previous chapter there are several future steps that will further our
understanding of the innate immune system in Dox-induced cardiotoxicity. This
chapter will report our findings from preliminary experiments done. Here we look into
the role of macrophages, ROS and cardiac fibroblasts in Dox-induced cardiotoxicity.
Macrophages
The exact role of macrophages in Dox-induced cardiotoxicity is not clear. We
observed an elevation in macrophage and monocytes in neutrophil depleted mice
treated for two weeks with Doxorubicin. In order to further delineate the importance of
macrophages in Dox-induced cardiotoxicity or mouse model we depleted
macrophages prior to Dox therapy using chlodronate liposomes. We first confirmed
depletion by quantifying and comparing macrophages (CD11b+ F4/80+) in heart tissue
48 hrs post depletion. We confirmed the depletion of macrophages in heart tissue of
chlodronate liposome treated group. Dox treatment was then initiated in the control
and macrophage depleted mice for 2 weeks. Depletion of macrophages was repeated
every 3 days during the course of treatment. Twenty-four hours following completion
of Dox treatment performed echocardiographic measurements to assess heart
function to assess acute toxicity. Echocardiographic measurements were repeated at
2-week intervals, up to 8 weeks after Dox treatment to monitor heart function.
Similar to control mice there was a significant decrease in EF and FS in the
macrophage depleted mice 24 h after Dox therapy. This decrease in heart function
persisted and was still evident 8 weeks after Dox treatment (Figure 12). This is in
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contrast to our results with neutrophil depletion where there was no evidence of Doxinduced cardiotoxicity either acutely or 12 weeks post therapy. This indicates that
neutrophils are the critical cells that cause damage post Dox treatment. Delineating
the exact role of macrophages in Dox-induced cardiotoxicity would be key to
understanding the innate immune environment in heart post Dox treatment.

Figure 13: Monocytes and Macrophages in Dox-induced cardiotoxicity. Ejection
fraction (EF) and fractional shortening (FS) were quantified by echocardiography up
to 8 weeks after therapy. Data are presented as mean ± SEM, n = 5 each, p < 0.05,
one-way ANOVA analysis with Tukey comparison was used to compare the groups.
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ROS
We investigated ROS levels during and after Dox treatment by measuring the intensity
of Dichlorofluorescein dye using flow cytometry. While no increase was seen 6 hrs
post Dox, we observed a significant increase in circulating ROS levels 24 hrs after 1
dose of Dox. This increase did not persist at the 1-week timepoint. The increase in
ROS was also seen 24 hrs after dose 4 of Dox indicating that this is a consistent acute
response to Dox therapy (Figure 13).
Since ROS is generated by neutrophils and can augment the generation of
neutrophil extracellular traps and pro-inflammatory cytokines 156, further investigation
into ROS levels in our neutrophil depleted mice would help understand the relationship
between ROS and neutrophils in Dox-induced cardiotoxicity.

Figure 14: ROS analysis in blood post Dox treatment. ROS analysis was done
measuring Dichlorofluorescein dye by flow cytometry at different time points after
treatment. Data are presented as mean ± SEM, n=5 each, *p<0.05, a Mann-Whitney
U-test was used to compare two groups.
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Cardiac Fibroblasts
In the context of Dox-induced cardiotoxicity we did a preliminary investigation on
the effects of Dox on cardiac fibroblasts. We first isolated primary fibroblasts from
mouse hearts and then treated these fibroblasts with Dox for 24 hrs. We then collected
the cells and isolated RNA and then analyzed cytokines and chemokines associated
with immune cell recruitment and inflammation by qPCR. We found a significant
increase in CXCL-1 and Granulocyte macrophage colony-stimulating factor (GMCSF) (Figure 14). CXCL-1 is a strong neutrophil chemoattractant. Reports have also
indicated that CXCL1 may aggravate cardiac fibrosis by a pro-inflammatory effect 157.
Additionally in CXCR2 (receptor for CXCL1) knockout mice where TGFβ1 and p-Smad
2/3 were suppressed, it was found that α-SMA levels were decreased suggesting that
CXCL1 may be mediating cardiac fibrosis though TGF-Smad2/3 signaling pathway
158.

GM-CSF promotes myeloid cell development and maturation

159.

In studies of

Kawasaki disease, a pediatric heart disease that is characterized by cardiac
inflammation and infiltration of neutrophils and monocytes, it was found that cardiac
fibroblasts were a major source of GM-CSF. Additionally, GM-CSF was found to drive
cardiac inflammation as it functioned as a pro-inflammatory cytokine. It was found to
be rapidly and selectively expressed in the heart during initial disease progression and
switched on inflammatory gene profile of resident macrophages160.
It is quite clear that cardiac fibroblasts play a major role in heart diseases. Hence, a
deeper investigation into the role of these cells in Dox-induced cardiotoxicity is
warranted based on the preliminary data and previous studies in heart diseases.
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Figure 15: Evaluation of cytokines in cardiac fibroblasts. Expression levels of CXCL1 and GM-CSF were evaluated using qPCR analysis. Data are presented as mean ±
SEM, n=4 each, *p<0.05, a Mann-Whitney U-test was used to compare two groups.
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Chapter Six: Methodology
This chapter is based upon “Bhagat A, Shrestha P, Jeyabal P, Peng Z, Watowich
SS, Kleinerman ES. Doxorubicin-induced cardiotoxicity is mediated by neutrophils
through release of neutrophil elastase. Front Oncol. 2022 Aug 10; 12:947604” as a
part of CC-BY Creative Commons attribution license.

Materials and Methods:
Mice: Our juvenile cardiotoxicity mouse model was used to determine the role of
neutrophils in Dox-induced cardiotoxicity 33,34. As Dox-induced cardiotoxicity has
been shown to be increased in females, female 4-6 weeks old C57BL/6 mice were
acquired from Experimental Radiation Oncology at MD Anderson Cancer Center
(Houston, TX, USA). Female 4-6 weeks old Balb/c mice were acquired from Charles
River Laboratory, Frederick. NE-deficient mice (NE-/-) of C57BL/6 background were
kindly provided by Dr Stephanie Watowich. All mice were maintained in a pathogenfree animal facility and used in accordance with IACUC approved protocols. All
experiments were performed in mice on Balb/c background, except for experiments
involving neutrophil elastase, for which C57BL/6 mice were used.
Echocardiography: Anaesthetized mice were assessed for cardiac function using
transthoracic echocardiography (Vevo 3100 echocardiography with a 40MHz linear
signal transducer and 550D probe; VisualSonics, Toronto, CA). M-mode short axis
images were recorded at the level of the papillary muscles. The left ventricular (LV)
muscle was bisected to obtain the optimal M-Mode(multimodal) selection. For each
mouse, at least five B-mode and five M-mode images were recorded. All images
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were saved for analysis. Conventional echocardiographic measurements of the left
ventricular function included ejection fraction (EF), fractional shortening (FS), enddiastolic dimension (LVID(d)), end-systolic dimension (LVID(s)), and anterior and
posterior wall thickness. For long axis B-mode measurements, the endocardium was
traced beginning from the mitral valve and excluding the papillary muscle. EF and
FS were calculated by Vevo Lab software and is expressed as change from baseline
measurement that is taken before Dox treatment.
Neutrophil depletion: InVivoPlus anti-mouse Ly6G(IA8) (Bioxcell BP) antibody was
used to deplete neutrophils. On days 2 and 9 of the experiment, anti-mouse Ly6G
(500 µg) was administered intra-peritoneally. To confirm successful depletion blood
samples were collected via retro-orbital bleeding. The red blood cells were lysed
using ACK lysis buffer and subsequently washed with phosphate-buffered saline
(PBS). The subsequent single cell suspension was incubated in PBS containing antimouse Ghost Violet Dye 510 (Tonbo Biosciences 13-0870) for 15-30 min at 4°C to
identify dead cells. This was followed by incubation in PBS with 2% FBS (FACS
buffer) containing FcR block for 10 minutes at 4°C. Subsequently, samples were
stained with fluorescently conjugated antibodies against murine cell surface markers
for 90 min at 4°C using the following reagents: anti-mouse CD45 PECy7 (Tonbo
Biosciences), anti-mouse Ly6G FITC (BioLegend) and anti-mouse CD11b APCCy7(BioLegend). Stained single-cell suspensions were analyzed on a BD LSR
Fortessa (BD Biosciences). Data analysis was performed using FlowJo v10 software
(FlowJo, Ashland, OR, USA)
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Administration of Doxorubicin in vivo: Doxorubicin from TEVA/Actavis(2mg/mL)
was resuspended in PBS to make up to a total volume of 100 µL at a dosage of
2.5mg/kg. Resuspended Doxorubicin was administered to the mice intravenously via
the tail vein twice a week for 2 weeks on days 4, 6, 11 and 13 as previously
described33,34.
Collection of Heart Sections: On day 14, 24h after the last dose of doxorubicin
mice were euthanized and hearts were removed and split into two sections. One
section was stored at -80°C (the optimal cutting temperature medium) to generate
slides for immunofluorescence staining. The other section was chopped into small
pieces (~2 mm) with a razor. Heart pieces were incubated in 2 mL Hanks’ Balanced
Salt solution (HBSS). Type 2 collagenase (Worthington) was added at a dilution of
1:10 to the heart pieces in HBSS and incubated for 30 min in a shaking incubator at
37°C and 125 RPM. Digested cell suspensions were passed through 70 µm mesh
filters; cells were subsequently washed with PBS. Following the wash, red blood
cells were digested using ACK lysis buffer and then washed again with PBS in
preparation for antibody staining.
Immune Profiling by antibody staining and flow cytometry: Single-cell
suspensions were incubated in PBS containing anti-mouse Ghost Violet Dye 510
(Tonbo Biosciences) for 15-30 min at 4°C to identify dead cells. This is followed by
incubation in PBS buffer with 2% FBS (FACS buffer) containing FcR block for 10 min
at 4°C. The samples were then stained for 90 min at 4°C with the following
antibodies against murine cell surface markers: anti-mouse CD45 PECy7 (Tonbo
Biosciences), anti-mouse Ly6G FITC (BioLegend), anti-mouse F4/80 APC
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(eBioscience), anti-mouse CD11b APC-Cy7(BioLegend), anti-mouse Ly6C
PerCP/Cy5.5(BioLegend). The stained single-cell suspensions were then analyzed
using a BD LSR Fortessa (BD Biosciences). Data analysis was performed using
FlowJo v10 software (FlowJo, Ashland, OR, USA).
Real-Time PCR: Quantitative real-time reverse transcription polymerase chain
reaction (RT–PCR) was conducted to verify the changes in mRNA expressions.
Extraction of the total RNA from cardiac tissues was performed utilizing the TRIzol
(Invitrogen, MO, USA) reagent. The list of the primer sequences used in the study:
mouse CXCL-1:(Forward:5’- ACCCGCTCGCTTCTCTGT-3), (Reverse: 5’AAGGGAGCTTCAGGGTCAAG-3).
Immunofluorescence staining: Frozen heart sections were fixed with acetone and
then incubated with anti-mouse Ly6G antibody (Abcam), anti-mouse CD31 (BD
Pharmingen) and anti-mouse NG2 (Santa Cruz Biotech. Fluorescence microscopy
(Leica Microsystems) was used to analyze the slides. At least five different
microscopy fields from different heart samples were examined using SimplePCI 6.0
software (Hamamatsu), and the average expression was quantified to determine
relative expression.
Masson Trichrome stain: Heart sections from mice were embedded in paraffin and
then fixed in Bouin’s solution. Following fixation, sections were stained using the
Sigma-Aldrich Trichrome Stain kit (Procedure No: - HT15), and images of stained
slides taken using the Hamamatsu Nanozoomer. At least five different fields from
different heart samples were analyzed using Leica Microsystems software (LAS X),
and the average expression was quantified to determine relative expression.
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Bone Marrow derived neutrophils: Femur and tibia from 4 to 6-week-old C57BL/6
control mice and NE-/- mice were collected and flushed with RPMI 1640 with 10%
FBS and 1% penicillin/streptomycin. Histopaque 1119 and 1077 were used to create
a density gradient to separate neutrophils from other immune cells. Purity of
neutrophils was verified using flow cytometry.
Neutrophil Trans-well Migration Assay: The neutrophils were stained with CFSE
(0.5 µM) dye and added to a 3 µm trans-well filter placed over the wells for 2 h.
Transmigration was observed using an Incucyte system. Fluorescent intensity was
quantified using Incucyte System S3 software. A chemoattractant for neutrophils:
WKYMVm (conc: 100 nM) was used.
TUNEL assay: Apoptotic cells were assessed using TUNEL staining with a
DeadEnd Fluorometric TUNEL system (Promega) according to manufacturer’s
instructions. Slides were fixed in 4% formaldehyde and then sections were incubated
in TdT reaction mix for 1 h at 37o C in the dark. Slides were then rinsed thrice with
PBS and observed under a fluorescence microscope. The number of apoptotic cells
was determined by counting the cells that were positive for both green fluorescence
and DAPI using ImageJ analysis software.
Western blotting: Isolated hearts were homogenized, and the protein lysates
obtained were run on a 7.5% polyacrylamide gel. The primary antibodies used for
blotting included: cleaved caspase-3, caspase-3 and GAPDH (Cell Signaling
Technology). Chemiluminescence was detected using ChemiDoc System (BioRad).
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NE Inhibitor Treatment: Mice were injected with AZD9668 intraperitoneally twice a
day(100mg/kg) for the duration of Dox treatment161 .
Statistics: Prism 8 software (GraphPad Software, San Diego, CA, USA) was used
to perform statistical analyses. Data are shown as mean ± the standard error of the
mean. An unpaired, two-tailed t test or Mann-Whitney test was used to compare two
groups. A one-way ANOVA with Tukey comparison was performed to compare more
than two groups. Differences were considered significant when p<0.05.
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